AMNEAL PHARMACEUTICALS, INC., 10-Q filed on 5/7/2021
Quarterly Report
v3.21.1
Cover - shares
3 Months Ended
Mar. 31, 2021
Apr. 30, 2021
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-38485  
Entity Registrant Name Amneal Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 32-0546926  
Entity Address, Address Line One 400 Crossing Boulevard,  
Entity Address, City or Town Bridgewater  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08807  
City Area Code 908  
Local Phone Number 947-3120  
Title of 12(b) Security Class A Common Stock, par value $0.01 per share  
Trading Symbol AMRX  
Security Exchange Name NYSE  
Entity Current Reporting Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001723128  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Class A Common Stock    
Entity Information [Line Items]    
Entity Common Stock, Shares Outstanding (in shares)   148,720,537
Class B Common Stock    
Entity Information [Line Items]    
Entity Common Stock, Shares Outstanding (in shares)   152,116,890
v3.21.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Net revenue $ 493,105 $ 498,533
Cost of goods sold 301,543 313,578
Cost of goods sold impairment charges 0 1,456
Gross profit 191,562 183,499
Selling, general and administrative 90,726 77,976
Research and development 48,182 36,379
In-process research and development impairment charges 0 960
Intellectual property legal development expenses 3,582 1,270
Acquisition, transaction-related and integration expenses 2,802 2,575
Charges related to legal matters, net 0 4,500
Restructuring and other charges 363 2,048
Operating income 45,907 57,791
Other (expense) income:    
Interest expense, net (33,885) (39,899)
Foreign exchange gain (loss), net 2,088 (5,181)
Other income, net 794 633
Total other expense, net (31,003) (44,447)
Income before income taxes 14,904 13,344
Provision for (benefit from) income taxes 359 (108,173)
Net income 14,545 121,517
Less: Net income attributable to non-controlling interests (7,839) (6,450)
Net income attributable to Amneal Pharmaceuticals, Inc. $ 6,706 $ 115,067
Net earnings per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:    
Basic (in usd per share) $ 0.05 $ 0.78
Diluted (in usd per share) $ 0.04 $ 0.78
Weighted-average common shares outstanding:    
Basic (in shares) 148,013 147,180
Diluted (in shares) 151,220 147,956
v3.21.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement of Other Comprehensive Income [Abstract]    
Net income $ 14,545 $ 121,517
Less: Net income attributable to non-controlling interests (7,839) (6,450)
Net income attributable to Amneal Pharmaceuticals, Inc. 6,706 115,067
Other comprehensive income (loss):    
Foreign currency translation adjustments arising during the period (6,366) (5,135)
Unrealized gain (loss) on cash flow hedge, net of tax 20,772 (62,658)
Less: Other comprehensive (income) loss attributable to non-controlling interests (7,302) 34,456
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. 7,104 (33,337)
Comprehensive income attributable to Amneal Pharmaceuticals, Inc. $ 13,810 $ 81,730
v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 452,097 $ 341,378
Restricted cash 3,717 5,743
Trade accounts receivable, net 530,600 638,895
Inventories 497,008 490,649
Prepaid expenses and other current assets 75,137 73,467
Related party receivables 1,102 1,407
Total current assets 1,559,661 1,551,539
Property, plant and equipment, net 471,165 477,754
Goodwill 522,758 522,814
Intangible assets, net 1,262,954 1,304,626
Financing lease right-of-use assets   10,000
Other assets 19,561 22,344
Total assets 3,960,070 4,006,033
Current liabilities:    
Accounts payable and accrued expenses 574,322 611,867
Current portion of long-term debt, net 29,817 44,228
Current portion of financing lease liabilities   2,000
Related party payable - short term 20,100 7,561
Total current liabilities 636,779 676,902
Long-term debt, net 2,728,212 2,735,264
Note payable - related party 36,828 36,440
Financing lease liabilities   2,000
Related party payable - long term 2,061 1,584
Other long-term liabilities 63,789 83,365
Total long-term liabilities 2,943,504 2,972,395
Commitments and contingencies (Notes 5 and 14)
Redeemable non-controlling interests 13,079 11,804
Stockholders' Equity    
Preferred stock, $0.01 par value, 2,000 shares authorized; none issued at both March 31, 2021 and December 31, 2020 0 0
Additional paid-in capital 634,484 628,413
Stockholders' accumulated deficit (280,115) (286,821)
Accumulated other comprehensive loss (34,361) (41,318)
Total Amneal Pharmaceuticals, Inc. stockholders' equity 323,015 303,271
Non-controlling interests 43,693 41,661
Total stockholders' equity 366,708 344,932
Total liabilities and stockholders' equity 3,960,070 4,006,033
Class A Common Stock    
Stockholders' Equity    
Common stock 1,485 1,475
Class B Common Stock    
Stockholders' Equity    
Common stock 1,522 1,522
Excluding Related Party    
Current assets:    
Operating lease right-of-use assets 32,396 33,947
Financing lease right-of-use assets 67,465 9,541
Current liabilities:    
Current portion of operating lease liabilities 6,637 6,474
Current portion of financing lease liabilities 3,020 1,794
Operating lease liabilities 28,435 30,182
Financing lease liabilities 61,871 2,318
Related Party    
Current assets:    
Operating lease right-of-use assets 24,110 24,792
Financing lease right-of-use assets 0 58,676
Current liabilities:    
Current portion of operating and financing lease liabilities - related party 2,883 3,978
Current portion of note payable - related party 0 1,000
Operating lease liabilities 22,308 23,049
Financing lease liabilities $ 0 $ 60,193
v3.21.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Preferred stock, par value (in usd per share) $ 0.01  
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in usd per share)   $ 0.01
Class A Common Stock    
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 900,000,000 900,000,000
Common stock, shares issued (in shares) 148,715,000 147,674,000
Class B Common Stock    
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 152,117,000 152,117,000
v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 14,545 $ 121,517
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 55,549 58,083
Unrealized foreign currency (gain) loss (1,970) 5,514
Amortization of debt issuance costs and discount 2,183 2,004
Intangible asset impairment charges 0 2,416
Stock-based compensation 5,330 4,539
Inventory provision 16,021 15,200
Other operating charges and credits, net 1,431 1,266
Changes in assets and liabilities:    
Trade accounts receivable, net 108,385 (60,893)
Inventories (20,283) (2,778)
Income taxes receivable associated with the CARES Act 0 (110,069)
Prepaid expenses, other current assets and other assets 602 (26,383)
Related party receivables 301 76
Accounts payable, accrued expenses and other liabilities (37,226) 34,839
Related party payables 3,260 3,695
Net cash provided by operating activities 148,128 49,026
Cash flows from investing activities:    
Purchases of property, plant and equipment (11,776) (7,367)
Deposits for future acquisition of property, plant, and equipment (917) 0
Acquisition of intangible assets 0 (1,050)
Acquisitions, net of cash acquired 0 (253,625)
Net cash used in investing activities (12,693) (262,042)
Cash flows from financing activities:    
Proceeds from issuance of debt 0 180,000
Payments of principal on debt, financing leases and other (23,630) (7,158)
Net borrowings on revolving credit facility 0 300,000
Payments of deferred financing costs 0 (4,102)
Proceeds from exercise of stock options 676 5
Employee payroll tax withholding on restricted stock unit vesting (2,102) (503)
Repayment of related party note (1,000) 0
Net cash (used in) provided by financing activities (26,149) 467,979
Effect of foreign exchange rate on cash (593) (860)
Net increase in cash, cash equivalents, and restricted cash 108,693 254,103
Cash, cash equivalents, and restricted cash - beginning of period 347,121 152,822
Cash, cash equivalents, and restricted cash - end of period 455,814 406,925
Cash and cash equivalents - end of period 452,097 405,238
Restricted cash - end of period 3,717 1,687
Supplemental disclosure of cash flow information:    
Cash paid for interest 29,917 35,386
Cash paid for income taxes, net 733 3,430
Supplemental disclosure of non-cash investing and financing activity:    
Tax distribution to non-controlling interests 9,757 0
Related Party    
Cash flows from financing activities:    
Payments of principal on financing lease - related party (93) (263)
Supplemental disclosure of non-cash investing and financing activity:    
Notes payable for acquisitions - related party $ 0 $ 36,033
v3.21.1
Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Total
Subsequent To Combination
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Additional Paid-in Capital
Stockholders' Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Non-Controlling Interests
Non-Controlling Interests
Subsequent To Combination
Shares beginning balance (in shares) at Dec. 31, 2019     147,070,000 152,117,000          
Stockholders' equity beginning balance at Dec. 31, 2019 $ 346,788   $ 1,470 $ 1,522 $ 606,966 $ (377,880) $ (68) $ 114,778  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 120,429         115,067   5,362  
Foreign currency translation adjustment (5,135)           (2,525) (2,610)  
Stock-based compensation 4,539       4,539        
Exercise of stock options (in shares)     1,000            
Exercise of stock options 5       5        
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)     240,000            
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (510)   $ 2   90     (602)  
Unrealized gain (loss) on cash flow hedge, net of tax (62,658)           (30,812) (31,846)  
Shares ending balance (in shares) at Mar. 31, 2020     147,311,000 152,117,000          
Stockholders' equity ending balance at Mar. 31, 2020 403,458   $ 1,472 $ 1,522 611,600 (262,813) (33,405) 85,082  
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2019 0                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net income 1,088                
Non-controlling interests from Rondo transaction 11,475                
Redeemable Non-Controlling Interests, ending balance at Mar. 31, 2020 12,563                
Shares beginning balance (in shares) at Dec. 31, 2020     147,674,000 152,117,000          
Stockholders' equity beginning balance at Dec. 31, 2020 344,932   $ 1,475 $ 1,522 628,413 (286,821) (41,318) 41,661  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 12,749         6,706   6,043  
Foreign currency translation adjustment (6,366)           (3,139) (3,227)  
Stock-based compensation 5,330       5,330        
Exercise of stock options (in shares)     244,000            
Exercise of stock options 676   $ 2   677   (34) 31  
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)     797,000            
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (2,149)   $ 8   64   (113) (2,108)  
Unrealized gain (loss) on cash flow hedge, net of tax 20,772           10,243 10,529  
Tax distribution   $ (9,236)             $ (9,236)
Shares ending balance (in shares) at Mar. 31, 2021     148,715,000 152,117,000          
Stockholders' equity ending balance at Mar. 31, 2021 366,708   $ 1,485 $ 1,522 $ 634,484 $ (280,115) $ (34,361) $ 43,693  
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2020 11,804                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net income 1,796                
Tax distribution (521)                
Redeemable Non-Controlling Interests, ending balance at Mar. 31, 2021 $ 13,079                
v3.21.1
Nature of Operations
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations Nature of Operations
Amneal Pharmaceuticals, Inc. (the “Company”) is a pharmaceutical company specializing in developing, manufacturing, marketing and distributing high-value generic and branded specialty pharmaceutical products across a broad array of dosage forms and therapeutic areas. The Company operates principally in the United States, India, and Ireland, and sells to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”). On May 4, 2018, Amneal completed the acquisition of Impax Laboratories, Inc. (“Impax”), a generic and specialty pharmaceutical company.
The group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Amneal Group”) held 50.6% of Amneal Common Units and the Company held the remaining 49.4% as of March 31, 2021. Although the Company has a minority economic interest in Amneal, it is Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, the Company consolidates the financial statements of Amneal and its subsidiaries. The Company records non-controlling interests for the portion of Amneal’s economic interests that it does not hold.
v3.21.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America, should be read in conjunction with Amneal’s annual audited financial statements for the year ended December 31, 2020 included in the Company’s 2020 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of March 31, 2021, cash flows for the three months ended March 31, 2021 and 2020 and the results of its operations, its comprehensive income and its changes in stockholders' equity for the three months ended March 31, 2021 and 2020. The consolidated balance sheet data at December 31, 2020 was derived from the Company's audited annual financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America.
The accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2020 Annual Report on Form 10-K. The following significant accounting policy has been updated to include the Company's accounting for foreign currency transactions that are of a long-term investment in nature.
Foreign Currencies

The Company has operations in the U.S., India, Ireland, and other international jurisdictions. Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in accumulated other comprehensive loss.
Use of Estimates
The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of
expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU 2020-04. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
Reclassification

Prior period balances related to (i) financing lease right-of-use assets of $10 million formerly included in other assets, (ii) current portion of financing lease liabilities of $2 million formerly included in accounts payable and accrued expenses, and (iii) long-term lease liabilities of $2 million formerly included in other long-term liabilities as of December 31, 2020 have been reclassified to their respective balance sheet captions to conform to the current period presentation in the consolidated balance sheets.
v3.21.1
Acquisitions and Divestitures
3 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
Acquisitions and Divestitures Acquisitions and Divestitures
Kashiv Specialty Pharmaceuticals, LLC Acquisition
On January 11, 2021, the Company and Kashiv Biosciences, LLC (a related party, see Note 16. Related Party Transactions) (“Kashiv”) entered into a definitive agreement for Amneal to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), a subsidiary of Kashiv focused on the development of innovative drug delivery platforms, novel 505(b)(2) drugs and complex generics. The acquisition was funded with cash on hand and closed on April 2, 2021.

Under the terms of the transaction, which will be accounted for as a business combination, Amneal paid an upfront purchase price of $70 million with cash on hand at the closing, which is subject to certain customary purchase price adjustments, and will make a cash payment of $30 million on January 11, 2022. Kashiv is also eligible to receive up to an additional $8 million in contingent payments upon the achievement of certain regulatory milestones and potential royalty payments from high single-digits to mid double-digits, depending on the net sales amount, of aggregate annual net sales for certain future pharmaceutical products.

Due to the timing of the acquisition, the initial accounting for the acquisition, including the valuation of the intangible assets acquired, is incomplete. As such, the Company is not able to disclose certain information relating to the acquisition including the preliminary fair value of assets acquired and liabilities assumed.
AvKARE and R&S Acquisitions
On December 10, 2019, the Company, through its investment in Rondo Partners, LLC (“Rondo”), entered into an equity purchase and operating agreements to acquire approximately a 65.1% controlling financing interest in both AvKARE Inc., a Tennessee corporation, and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”) (collectively the “Acquisitions”). Prior to closing, AvKARE, Inc. converted to a limited liability company, AvKARE, LLC. AvKARE, LLC is one of the largest private label providers of generic pharmaceuticals in the U.S. federal agency sector, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. R&S is a national pharmaceutical wholesaler focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.
On January 31, 2020, the Company completed the Acquisitions.  The purchase price of $294 million, included cash of $254 million and the issuance of long-term promissory notes to the sellers with an aggregate principal amount of $44 million (estimated fair value of $35 million) (the “Sellers Notes”) and a short-term promissory note (the “Short-Term Seller Note”) with a principal amount of $1 million to the sellers.  The cash purchase price was funded by $76 million of cash on hand and
$178 million of proceeds from a $180 million term loan.  The remaining $2 million consisted of working capital costs. The Company is not party to or a guarantor of the term loan, Sellers Notes or Short-Term Sellers Note. For further detail of the purchase price, refer to the table below.
For the three months ended March 31, 2020, there were $1 million of transaction costs associated with the Acquisitions recorded in acquisition, transaction-related and integration expenses (none for the three months ended March 31, 2021).
The Acquisitions were accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer of AvKARE, LLC and R&S.
The purchase price was calculated as follows (in thousands):
Cash$254,000 
Sellers Notes (1)
35,033 
Settlement of Amneal trade accounts receivable from R&S (2)
6,855 
Short-Term Seller Note (3)
1,000 
Working capital adjustment (4)
(2,640)
Fair value consideration transferred$294,248 
(1)In accordance with ASC 805, Business Combinations, all consideration transferred was measured at its acquisition-date fair value. The Sellers Notes are stated at the fair value estimate of $35 million, which is the $44 million aggregate principal amount less a $9 million discount.  The fair value of the Sellers Notes was estimated using the Monte-Carlo simulation approach under the option pricing framework.
(2)Represents trade accounts receivable from R&S that was effectively settled upon closing of the Acquisitions.
(3)Represents the principal amount due on the Short-Term Seller Note, which approximates fair value. The entire Short-Term Seller Note was repaid in February 2021.
(4)Represents a working capital adjustment pursuant to the terms of the purchase agreement. The entire amount was received in cash by the Company in September 2020.
The following is a summary of the purchase price allocation for the Acquisitions (in thousands):
Final Fair Values as of
January 31, 2020
Trade accounts receivable, net$46,702 
Inventories71,908 
Prepaid expenses and other current assets11,316 
Related party receivables61 
Property, plant and equipment5,278 
Goodwill103,679 
Intangible assets, net130,800 
Operating lease right-of-use assets - related party5,544 
Total assets acquired375,288 
Accounts payable and accrued expenses62,489 
Related party payables1,532 
Operating lease liabilities - related party5,544 
Total liabilities assumed69,565 
Redeemable non-controlling interests11,475 
Fair value of consideration transferred$294,248 
The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands):

Fair Values
Weighted-Average
Useful Life
Government licenses$66,700 7 years
Government contracts22,000 4 years
National contracts28,600 5 years
Customer relationships13,000 10 years
Trade name500 6 years
$130,800 
The estimated fair value of the government licenses was determined using the “with-and-without method,” which is a valuation technique that provides an estimate of the fair value of an intangible asset that is equal to the difference between the present value of the prospective revenues and expenses for the business with and without the subject intangible asset in place. The estimated fair values of the government contracts, national contracts, and customer relationships were determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an intangible asset based on market participant expectations of the cash flows that an intangible asset would generate over its remaining useful life. The estimated fair value of the trade name was determined using the “relief from royalty method,” which is a valuation technique that provides an estimate of the fair value of an intangible asset equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the purchase price were based on management's best estimates as of the closing date of the Acquisitions on January 31, 2020.
Some of the more significant assumptions inherent in the development of those asset valuations included the estimated net cash flows for each year for each asset (including net revenues, cost of sales, selling and marketing costs and working capital / contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, competitive trends impacting the asset and each cash flow stream, as well as other factors. The underlying assumptions used to prepare the discounted cash flow analysis may change; accordingly, for these and other reasons, actual results may vary significantly from estimated results.
The Sellers Notes and redeemable non-controlling interests were estimated using the Monte-Carlo simulation approach under the option pricing framework. The non-controlling interests are redeemable at the option of either the non-controlling interest holder and Amneal. The fair value of the redeemable non-controlling interests considers these redemption rights.
Of the $104 million of goodwill acquired in connection with the Acquisitions, approximately $70 million was allocated to the Company’s AvKARE segment (refer to Note 15. Segment Information) and approximately $34 million was allocated to the Generics segment.  Goodwill was allocated to the Generics segment as net revenue of products manufactured from Amneal and distributed by the Acquisitions is reflected in Generics’ segment results.  Goodwill is calculated as the excess of the fair value of the consideration transferred and the fair value of the redeemable non-controlling interests over the fair value of the net assets recognized. Factors that contributed to the recognition of goodwill include Amneal’s intent to diversify its business and open growth opportunities in the large, complex and growing federal healthcare market.
Unaudited Pro Forma Information
The unaudited pro forma combined results of operations for the three months ended March 31, 2020 (assuming the closing of the Acquisitions occurred on January 1, 2020) are as follows (in thousands):
Net revenue$525,303 
Net income$122,521 
Net income attributable to Amneal Pharmaceuticals, Inc.$115,388 
The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the closing of the Acquisitions taken place on January 1, 2020. Adjustments to arrive at the unaudited pro forma information primarily related to increases in selling, general and administrative expenses for amortization of acquired intangible assets, net of the applicable tax impact.
v3.21.1
Revenue Recognition
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
Concentration of Revenue
The Company's three largest customers accounted for approximately 82% and 81% of total gross sales of products for the three months ended March 31, 2021 and 2020, respectively.
Disaggregated Revenue
The Company's significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the three months ended March 31, 2021 and 2020 are set forth below (in thousands):
Three Months Ended March 31,
20212020
Generics
Anti-Infective$5,913 $13,253 
Hormonal106,703 87,481 
Antiviral (1)
(7,941)15,824 
Central Nervous System96,291 101,575 
Cardiovascular System35,311 29,679 
Gastroenterology19,458 23,536 
Oncology19,030 15,966 
Metabolic Disease/Endocrine6,557 17,229 
Respiratory8,178 10,067 
Dermatology12,878 15,245 
Other therapeutic classes9,731 21,746 
International and other399 985 
Total Generics net revenue312,508 352,586 
Specialty
Hormonal/Metabolic16,796 14,227 
Central Nervous System67,711 68,311 
Other therapeutic classes11,424 5,439 
Total Specialty net revenue95,931 87,977 
AvKARE (2)
Distribution45,499 31,586 
Government Label31,072 21,378 
Institutional5,179 3,413 
Other2,916 1,593 
Total AvKARE net revenue84,666 57,970 
Total net revenue$493,105 $498,533 
(1) Antiviral revenue for the three months ended March 31, 2021 decreased from the prior year, primarily due to a $23 million decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels due to decreased influenza activity during the COVID-19 pandemic.
(2) The AvKARE segment consists of the businesses acquired in the Acquisitions on January 31, 2020. Net revenue for the three months ended March 31, 2020 represent two months of activity.
A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2021 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2020$628,804 $22,690 $174,984 $131,088 
Provision related to sales recorded in the period727,258 25,048 24,786 28,770 
Credits/payments issued during the period(838,304)(25,402)(25,758)(26,852)
Balance at March 31, 2021$517,758 $22,336 $174,012 $133,006 
v3.21.1
Alliance and Collaboration
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Alliance and Collaboration Alliance and Collaboration
The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide research and development services over multiple periods. The Company's significant arrangements are discussed below.
Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited
In January 2012, Impax entered into an agreement with AstraZeneca UK Limited ("AstraZeneca") to distribute branded products under the terms of a distribution, license, development and supply agreement (the "AZ Agreement"). The parties subsequently entered into a First Amendment to the AZ Agreement dated May 31, 2016 (as amended, the "AZ Amendment"). Under the terms of the AZ Agreement, AstraZeneca granted to Impax an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment of migraine headaches in the United States and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on Impax’s behalf and AstraZeneca paid to Impax the gross profit on such Zomig® products. Pursuant to the AZ Amendment, under certain conditions, and depending on the nature and terms of the study agreed to with the FDA, Impax agreed to conduct, at its own expense, the juvenile toxicity study and pediatric study required by the FDA under the Pediatric Research Equity Act ("PREA") for approval of the nasal formulation of Zomig ® for the acute treatment of migraine in pediatric patients ages six through eleven years old, as further described in the study protocol mutually agreed to by the parties (the "PREA Study"). In consideration for Impax conducting the PREA Study at its own expense, the AZ Amendment provides for the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig ® products under the AZ Agreement to be reduced by an aggregate amount of $30 million to be received in quarterly amounts specified in the AZ Amendment beginning from the quarter ended June 30, 2016 and through the quarter ended December 31, 2021. In the event the royalty reduction amounts exceed the royalty payments payable by Impax to AstraZeneca pursuant to the AZ Agreement in any given quarter, AstraZeneca will be required to pay Impax an amount equal to the difference between the royalty reduction amount and the royalty payment payable by Impax to AstraZeneca. Impax’s commitment to perform the PREA Study may be terminated, without penalty, under certain circumstances as set forth in the AZ Amendment. The Company recognizes the amounts received from AstraZeneca for the PREA Study as a reduction to research and development expense. The PREA Study was completed during March 2021.
In May 2013, Impax’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and Impax launched authorized generic versions of those products in the United States. As discussed above, pursuant to the AZ Amendment, the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig ® products under the AZ Agreement is reduced by certain specified amounts beginning from the quarter ended June 30, 2016 and through the quarter ended December 31, 2020, with such reduced royalty amounts totaling an aggregate amount of $30 million. The Company recorded cost of sales for royalties under this agreement of $3 million and $4 million for the three months ended March 31, 2021 and 2020, respectively.
Biosimilar Licensing and Supply Agreement
On May 7, 2018, the Company entered into a licensing and supply agreement, with Mabxience S.L., for its biosimilar candidate for Avastin® (bevacizumab). The licensing agreement was subsequently amended on March 4, 2021 and the supply agreement was subsequently amended on March 2, 2021.The Company will be the exclusive partner in the U.S. market. The Company will pay development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to Mabxience, up to $78 million. For the three months ended March 31, 2021, the Company recognized $2 million of research and development expense related to the agreement (none for the three months ended March 31, 2020).
Agreements with Kashiv Biosciences, LLC
For detail on the Company’s related party agreements with Kashiv Biosciences, LLC, refer to Note 16. Related Party Transactions.
v3.21.1
Restructuring and Other Charges
3 Months Ended
Mar. 31, 2021
Restructuring and Related Activities [Abstract]  
Restructuring and Other Charges Restructuring and Other Charges
On July 10, 2019, the Company announced a plan to restructure its operations that is intended to reduce costs and optimize its organizational and manufacturing infrastructure. Pursuant to the restructuring plan as revised, the Company expects to reduce its headcount over the course of this multi-year program by approximately 300 to 350 employees through December 31, 2021, primarily by closing its manufacturing facility located in Hauppauge, NY. Through March 31, 2021, the Company had reduced headcount by 280 employees under this plan.
For the three months ended March 31, 2021, there were no employee restructuring separation charges. For the three months ended March 31, 2020, employee restructuring charges were immaterial. The total employee separation-related liability as of both March 31, 2021 and December 31, 2020 was $1.6 million and included within accounts payable and accrued expenses. There were no payments made or adjustments to the liability during the three months ended March 31, 2021.

Other employee severance charges were $0.4 million and $2 million during the three months ended March 31, 2021 and 2020, respectively. Severance charges primarily consisted of the cost of benefits provided pursuant to our severance programs for former senior executives and management employees.
v3.21.1
Earnings per Share
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
Basic earnings per share of the Company’s class A common stock is computed by dividing net income attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of class A common stock outstanding during the period. Diluted earnings per share of class A common stock is computed by dividing net income attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of class A common stock outstanding, adjusted to give effect to potentially dilutive securities.
The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per share of class A common stock (in thousands, except per share amounts):
Three Months Ended
March 31,
20212020
Numerator:
Net income attributable to Amneal Pharmaceuticals, Inc.$6,706 $115,067 
Denominator:
Weighted-average shares outstanding - basic148,013 147,180 
Effect of dilutive securities:
Stock options792 230 
Restricted stock units2,415 546 
Weighted-average shares outstanding - diluted
151,220 147,956 
Net earnings per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:
Basic$0.05 $0.78 
Diluted$0.04 $0.78 
Shares of the Company's class B common stock do not share in the earnings or losses of the Company and, therefore, are not participating securities. As such, separate presentation of basic and diluted earnings per share of class B common stock under the two-class method has not been presented.
The following table presents potentially dilutive securities excluded from the computations of diluted earnings per share of class A common stock (in thousands):
Three Months Ended
March 31,
20212020
Stock options
347 
(1)
683 
(1)
Performance stock units
5,124 
(2)
3,054 
(2)
Shares of class B common stock152,117 
(3)
152,117 
(3)
(1)Excluded from the computation of diluted earnings per share of class A common stock because the exercise price of the stock options exceeded the average market price of the class A common stock during the period (out-of-the-money).
(2)Excluded from the computation of diluted earnings per share of class A common stock because the performance vesting conditions were not met for the three months ended March 31, 2021 and 2020.
(3)Shares of class B common stock are considered potentially dilutive shares of class A common stock. Shares of class B common stock have been excluded from the computations of diluted earnings per common share because the effect of their inclusion would have been anti-dilutive under the if-converted method.
v3.21.1
Income Taxes
3 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
For the three months ended March 31, 2021 and 2020, the Company's provision for (benefit from) income taxes and effective tax rates were $0.4 million and 2.4% and $(108) million and (810.6)%, respectively. The benefit from income taxes for the three months ended March 31, 2020 was primarily impacted by a $110 million discrete income tax benefit from the carryback of U.S. Federal Net Operating Loss (“NOL”) deferred tax assets (“DTAs”) under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”).
As of September 30, 2019, the Company established a valuation allowance based upon all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. The Company estimated that as of September 30, 2019 it had generated a cumulative consolidated three-year pre-tax loss, which continued as of December 31, 2020.  As a result of the initial September 30, 2019 and December 31, 2020 analyses, the Company determined that it remained more likely than not that it would not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of December 31, 2020, this valuation allowance was $423 million, and it reduced the carrying value of these gross DTAs, net of the impact of the reversal of taxable temporary differences, to zero. As of March 31, 2021, based on its evaluation of available positive and negative evidence, the Company has maintained its position with respect to the valuation allowance.
On March 27, 2020, President Trump signed into law the CARES Act. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic which, among other things, includes provisions relating to income and non-income-based tax laws. Some of the key income tax-related provisions include net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. Some of these tax provisions are effective retroactively for years ending before the date of enactment. Other non-income-based tax provisions include deferral of the employer share of Social Security payroll taxes due from the CARES Act date of enactment through December 31, 2021, and a potential 50% credit on qualified wages against employment taxes each quarter with any excess credits eligible for refunds.
The CARES Act permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs originating in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate refunds of previously paid income taxes. As a result of the CARES Act, the Company carried back approximately $345 million in NOLs generated in 2018 to prior taxable income years.
ASC 740, Income Taxes, requires the effect from adjusting deferred tax assets or changes to valuation allowances due to the CARES Act to be recognized as a component of income taxes expense or benefit in the interim period that includes the period in which the legislation is enacted (quarter ended March 31, 2020), and it cannot be allocated to subsequent interim periods by an adjustment of the estimated annual effective tax rate. In the three months ended March 31, 2020, the Company reclassified the 2018 NOL carryback amount for previously paid income taxes to income tax receivable and reversed the corresponding valuation allowance. In carrying back the 2018 loss to an earlier year, the Company is able to benefit the losses at a 35% tax rate rather than the current U.S. corporate tax rate of 21%.  Accordingly, the Company recorded a discrete income tax benefit of $110 million, for the three months ended March 31, 2020. During July 2020, the Company received a cash refund for $106 million of the $110 million NOL carryback, plus interest of approximately $4 million. During February 2021, the Company received an additional cash refund for $2 million, plus interest, with the remainder of the NOL carryback expected to be received before December 31, 2021.
The Company entered into a tax receivable agreement (“TRA”) for which it is generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A Common Stock and (ii) tax benefits attributable to payments made under the TRA.  In conjunction with the valuation allowance recorded on the DTAs at September 30, 2019, the Company reversed the TRA liability.
The projection of future taxable income involves significant judgment. Actual taxable income may differ from the Company’s estimates, which could significantly impact the timing of the recognition of the contingent liability under the TRA. As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize all of its DTAs subject to the TRA; therefore, as of March 31, 2021, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more likely than not in the future, at such time, Amneal will recognize a liability under the TRA as a result of basis adjustments under Internal Revenue Code Section 754. As of both March 31, 2021 and December 31, 2020, the contingent liability, if recognized, amounts to $206 million.
The timing and amount of any payments under the TRA may vary depending upon a number of factors, including the timing and number of Amneal common units sold or exchanged for the Company's Class A Common Stock, the price of the Company's Class A Common Stock on the date of sale or exchange, the timing and amount of the Company's taxable income, and the tax rate in effect at the time of realization of the Company's taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA's attributes). Further sales or exchanges occurring subsequent to March 31, 2021 could result in future Amneal tax deductions and obligations to pay 85% of such benefits to the holders of Amneal common units. These obligations could be incremental to and substantially larger than the approximate $206 million contingent liability as of March 31, 2021 described above. Under certain conditions, such as a change of control or other early termination event, the Company could be obligated to make TRA payments in advance of tax benefits being realized. Payments could also be in excess of the tax savings that we ultimately realize.

Any future recognition of these TRA liabilities will be recorded through charges in the Company’s consolidated statements of operations.  However, if the tax attributes are not utilized in future years, it is reasonably possible no amounts would be paid under the TRA.  Should the Company determine that a DTA with a valuation allowance is realizable in a subsequent period, the related valuation allowance will be released and if a resulting TRA payment is determined to be probable, a corresponding TRA liability will be recorded.
v3.21.1
Trade Accounts Receivable, Net
3 Months Ended
Mar. 31, 2021
Receivables [Abstract]  
Trade Accounts Receivable, Net Trade Accounts Receivable, Net
Trade accounts receivable, net is comprised of the following (in thousands):
March 31,
2021
December 31,
2020
Gross accounts receivable$1,072,138 $1,291,785 
Allowance for credit losses(1,444)(1,396)
Contract charge-backs and sales volume allowances(517,758)(628,804)
Cash discount allowances(22,336)(22,690)
Subtotal(541,538)(652,890)
Trade accounts receivable, net$530,600 $638,895 
Receivables from customers representing 10% or more of the Company’s gross trade accounts receivable reflected three customers at March 31, 2021, equal to 34%, 28%, and 22%, respectively.  
Receivables from customers representing 10% or more of the Company’s gross trade accounts receivable reflected three customers at December 31, 2020, equal to 39%, 26%, and 20%, respectively.
v3.21.1
Inventories
3 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are comprised of the following (in thousands):
March 31,
2021
December 31,
2020
Raw materials
$205,874 $209,180 
Work in process
51,633 40,937 
Finished goods
239,501 240,532 
Total inventories$497,008 $490,649 
v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
Fair Value Measurement Based on
March 31, 2021TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Liabilities
Interest rate swap (1)
$33,131 $— $33,131 $— 
Deferred compensation plan liabilities (2)
$14,500 $— $14,500 $— 
December 31, 2020
Liabilities
Interest rate swap (1)
$53,903 — $53,903 — 
Deferred compensation plan liabilities (2)
$14,007 — $14,007 — 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 12. Financial Instruments for information on the Company's interest rate swap.
(2)As of March 31, 2021, deferred compensation plan liabilities of $2 million and $13 million were recorded in current and non-current liabilities, respectively. As of December 31, 2020, deferred compensation plan liabilities of $2 million and $12 million were recorded in current and non-current liabilities, respectively. These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.
There were no transfers between levels in the fair value hierarchy during the three months ended March 31, 2021.
Assets and Liabilities Not Measured at Fair Value on a Recurring Basis
The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments.
The Company's outstanding Term Loan falls into the Level 2 category within the fair value level hierarchy. The fair value was determined using market data for valuation. The fair value of the Term Loan as of both March 31, 2021 and December 31, 2020 was approximately $2.6 billion.
The Rondo Term Loan entered into on January 31, 2020 falls into the Level 2 category within the fair value level hierarchy. The fair value of the Rondo Term Loan at March 31, 2021 and December 31, 2020 was approximately $170 million and $172 million, respectively.
The Sellers Notes falls into the Level 2 category within the fair value level hierarchy. The carrying value of the Sellers Notes at March 31, 2021 and December 31, 2020 was $37 million and $36 million, respectively, which approximate their fair values.
Refer to Note 17. Debt in our 2020 Annual Report on Form 10-K for detailed information about our indebtedness, including definitions of terms.
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
There were no non-recurring fair value measurements during the three months ended March 31, 2021 and 2020.
v3.21.1
Financial Instruments
3 Months Ended
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial InstrumentsThe Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates.
Interest Rate Risk
The Company is exposed to interest rate risk on its debt obligations.  The Company's debt obligations consist of variable-rate and fixed-rate debt instruments.  The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range.  In order to achieve this objective, the Company has entered into an interest rate swap on the Term Loan.
Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows because the impact of interest rate risk is not material.
Interest Rate Derivative – Cash Flow Hedge
The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month LIBOR associated with its Term Loan.
As of March 31, 2021, the total loss, net of income taxes, related to the Company’s cash flow hedge was $33 million, of which $16 million was recognized in accumulated other comprehensive loss and $17 million was recognized in non-controlling interests.
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
March 31, 2021December 31, 2020
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther long-term liabilities$33,131 Other long-term liabilities$53,903 
v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Commitments
Commercial Manufacturing, Collaboration, License, and Distribution Agreements
The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered into with third parties. The Company has also licensed certain technologies or intellectual property from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Certain of these arrangements are with related parties (refer to Note 16. Related Party Transactions).
Contingencies
Legal Proceedings
The Company's legal proceedings are complex, constantly evolving and subject to uncertainty. As such, the Company cannot predict the outcome or impact of the legal proceedings set forth below. Additionally, the Company is subject to legal proceedings that are not set forth below. While the Company believes it has valid claims and/or defenses to the matters described below, the nature of litigation is unpredictable, and the outcome of the following proceedings could include damages, fines, penalties and injunctive or administrative remedies. For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues for a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims.
The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. For the three months ended March 31, 2020, the Company recorded net charges of $5 million (none for the three months ended March 31, 2021) for commercial legal proceedings and claims. The Company had total liabilities for legal proceedings as of both March 31, 2021 and December 31, 2020 of $11 million. The ultimate resolution of any or all claims, legal proceedings or investigations could differ materially from our estimate and have a material adverse effect on the Company's results of operations and/or cash flows in any given accounting period, or on the Company's overall financial condition.  
Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products.
The Company believes it has meritorious claims and defenses in these matters and intends to vigorously prosecute and defend them. However, because the ultimate outcome and costs associated with litigation are inherently uncertain and difficult to predict, except as otherwise stated, the Company is not in a position to predict the likelihood of an unfavorable outcome or provide an estimate of the amount or range of potential loss in the event of an unfavorable outcome in any of these matters, and any adverse outcome could negatively affect the Company and could have a material adverse effect on the Company's results of operations, cash flows and/or overall financial condition.
Medicaid Reimbursement and Price Reporting Matters
The Company is required to provide pricing information to state agencies, including agencies that administer federal Medicaid programs. Certain state agencies have alleged that manufacturers have reported improper pricing information, which allegedly caused them to overpay reimbursement costs.  Other agencies have alleged that manufacturers have failed to timely file required
reports concerning pricing information.  Reserves are periodically established by the Company for any potential claims or settlements of overpayment. The Company intends to vigorously defend against any such claims.  The ultimate settlement of any potential liability for such claims may be higher or lower than estimated.
Patent Litigation
There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and intellectual property claims. One or more patents often cover the brand name products for which the Company is developing generic versions and the Company typically has patent rights covering the Company’s branded products.
Under federal law, when a drug developer files an Abbreviated New Drug Application ("ANDA") for a generic drug seeking approval before expiration of a patent which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a "Paragraph IV" certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45-day period, the FDA can review and tentatively approve the ANDA, but generally is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. The Company’s Generics segment is typically subject to patent infringement litigation brought by branded pharmaceutical manufacturers in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation. Likewise, the Company’s Specialty segment is currently involved in patent infringement litigation against generic drug manufacturers that have filed Paragraph IV certifications to market their generic drugs prior to expiration of the Company’s patents at issue in the litigation.
The uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. For the Company’s Generics segment, the potential consequences in the event of an unfavorable outcome in such litigation include delaying launch of its generic products until patent expiration. If the Company were to launch its generic product prior to successful resolution of a patent litigation, the Company could be liable for potential damages measured by the profits lost by the branded product manufacturer rather than the profits earned by the Company if it is found to infringe a valid, enforceable patent, or enhanced treble damages in cases of willful infringement. For the Company’s Specialty segment, an unfavorable outcome may significantly accelerate generic competition ahead of expiration of the patents covering the Company’s branded products. All such litigation typically involves significant expense.
The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party.
Patent Defense Matter

Biogen International GMBH, et al. v. Amneal Pharmaceuticals LLC, et al. (Dimethyl Fumarate)

In June 2017, Biogen International GMBH (“Biogen”) filed suit against Amneal and various other generic manufacturers in the United States District Court for the District of Delaware (“D. Del.”) alleging patent infringement based on the filing of ANDAs by Amneal and others for generic alternatives to Biogen’s Tecfidera® (dimethyl fumarate) capsules product (Biogen International GMBH, et al. v. Amneal Pharmaceuticals LLC, et al., No. 1:17-cv-00823-MN). Biogen also filed suit in June 2017 against Mylan Pharmaceuticals Inc. (“Mylan”) in the United States District Court for the Northern District of West Virginia (“N.D. W. Va.”) relating to Mylan’s own ANDA for Tecfidera®. On June 18, 2020, the N.D. W. Va. court issued an order finding the sole Biogen patent at issue invalid. Biogen has appealed the order to the United States Court of Appeals for the Federal Circuit. On September 22, 2020, the D. Del. court entered judgment in favor of defendants (including Amneal), adopting the finding of invalidity made by the N.D. W. Va. court but ordering that claims could be reinstated based on the result of the appeal of the N.D. W. Va. court’s order. Amneal, like Mylan and a number of other generic manufacturers, has now launched its generic dimethyl fumarate capsules product “at-risk,” pending the outcome of Biogen’s appeal of the N.D. W. Va. court’s order before the Federal Circuit.
Other Litigation Related to the Company’s Business

Opana ER® FTC Matters

On February 25, 2014, Impax received a Civil Investigative Demand (“CID”) from the Federal Trade Commission (“FTC”) concerning its investigation into the drug Opana® ER and its generic equivalents. On March 30, 2016, the FTC filed a complaint against Impax, Endo Pharmaceuticals Inc. ("Endo"), and others in the United States District Court for the Eastern District of Pennsylvania, alleging that Impax and Endo violated antitrust laws when they entered into a June 2010 settlement agreement that resolved patent litigation in connection with the submission of Impax’s ANDA for generic original Opana® ER. In October 2016, the Court granted Impax’s motion to sever, formally terminating the suit against Impax. In January 2017, the FTC filed a Part 3 Administrative Complaint against Impax with similar allegations regarding the 2010 settlement. Following trial, in May 2018, the Administrative Law Judge ruled in favor of Impax and dismissed the Complaint in its entirety. In March 2019, the FTC issued an Opinion & Order reversing the Administrative Law Judge’s decision, and in June 2019, Impax filed a Petition for Review of the FTC’s Opinion & Order with the United States Court of Appeals for the Fifth Circuit. The Opinion & Order did not contain any monetary damages but enjoined Impax from entering into similar future agreements. On April 13, 2021, the Fifth Circuit issued a decision affirming the FTC’s Opinion & Order.

On July 12, 2019, the Company received a CID from the FTC concerning an August 2017 settlement agreement between Impax and Endo, which resolved a subsequent patent infringement and breach of contract dispute between the parties regarding the above-referenced June 2010 settlement agreement related to Opana® ER. The Company cooperated with the FTC regarding the CID. On January 25, 2021, the FTC filed a complaint against Endo, Impax and Amneal in the United States District Court for the District of Columbia, alleging that the 2017 settlement violated antitrust laws. Impax and Amneal believe that they have strong defenses to the FTC’s allegations and intend to vigorously defend the action.
Opana ER® Antitrust Litigation

From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out plaintiffs”) of Opana ER® were filed against Endo and Impax.

The direct purchaser plaintiffs comprise Value Drug Company and Meijer Inc. The end-payor plaintiffs comprise the Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund; Wisconsin Masons’ Health Care Fund; Massachusetts Bricklayers; Pennsylvania Employees Benefit Trust Fund; International Union of Operating Engineers, Local 138 Welfare Fund; Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana; Kim Mahaffay; and Plumbers & Pipefitters Local 178 Health & Welfare Trust Fund. The opt-out plaintiffs comprise Walgreen Co.; The Kroger Co.; Safeway, Inc.; HEB Grocery Company L.P.; Albertson’s LLC; Rite Aid Corporation; Rite Aid Hdqtrs. Corp.; and CVS Pharmacy, Inc.

In December 2014, the United States Judicial Panel on Multidistrict Litigation (the "JPML") transferred the actions to the United States District Court for the Northern District of Illinois (“N.D. Ill.”) for coordinated pretrial proceedings, as In Re: Opana ER Antitrust Litigation (MDL No. 2580).

In each case, the complaints allege that Endo engaged in an anticompetitive scheme by, among other things, entering into an anticompetitive settlement agreement with Impax to delay generic competition of Opana ER® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. On March 25, 2019, plaintiffs filed motions for class certification and served expert reports. Defendants’ oppositions to class certification and expert reports were filed and served on August 29, 2019. On February 5, 2020, the court entered a case schedule setting a trial date of March 15, 2021, which subsequently was re-set for November 1, 2021. On April 15, 2020, defendants filed motions for summary judgment and each side moved to exclude certain opposing experts. These various motions remain pending.
Attorney General of the State of Connecticut Interrogatories and Subpoena Duces Tecum

On July 14, 2014, Impax received a subpoena from the State of Connecticut Attorney General ("Connecticut AG") concerning its investigation into sales of Impax's generic product, digoxin. According to the Connecticut AG, the investigation concerned whether anyone engaged in a contract, combination or conspiracy in restraint of trade or commerce which had the effect of (i) fixing, controlling or maintaining prices or (ii) allocating or dividing customers or territories relating to the sale of digoxin. Impax cooperated in the investigation and produced documents and information in response to the Subpoena in 2014 and 2015. However, no assurance can be given as to the timing or outcome of this investigation.
United States Department of Justice Investigations

On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the "DOJ"). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax has cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation.

On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the "Civil Division"). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the Federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.
In Re Generic Pharmaceuticals Pricing Antitrust Litigation
Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania (In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa.)).
On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. Plaintiff States seek unspecified monetary damages and penalties and equitable relief, including disgorgement and restitution. These lawsuits have been incorporated into MDL No. 2724.
Fact and document discovery in MDL No. 2724 are proceeding. In July 2020, the Court ordered certain plaintiffs’ complaints regarding three generic drug products to proceed as bellwether cases, along with the Plaintiff States’ November 2019 amended complaint. In February 2021, the Court vacated the prior order regarding bellwether cases. Revised bellwether cases are under consideration and no scheduling order has yet been issued for this matter.
Prescription Opioid Litigation
The Company and certain of its affiliates have been named as defendants in various matters filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include state Attorneys General, county and municipal governments, hospitals, Indian tribes, pension funds, third-party payors and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors and retail pharmacies as defendants, and there are numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors and retail pharmacies in which the Company and its affiliates are not named.

Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804). There are approximately 880 cases in the MDL in which the Company or its affiliates have been named as defendants. The Company also is named in approximately 120 state court cases pending in 11 states. The Company has filed motions to dismiss
in many of these cases. No trial dates have been set except in New Mexico (September 2022), Alabama (July 2022) and West Virginia (November 2021); it is not known at this time if the Company will be involved in the West Virginia case trial.
Securities Class Actions

On April 17, 2017, New York Hotel Trades Council & Hotel Association of New York City, Inc. Pension Fund filed an amended putative class action complaint in the United States District Court for the Northern District of California against Impax and four former Impax officers alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 (Fleming v. Impax Laboratories Inc., et al., No. 4:16-cv-6557-HSG). Plaintiff alleges that Impax (1) concealed collusion with a competitor to fix the price of the generic drug digoxin; (2) concealed anticipated erosion in the price of generic drug diclofenac; and (3) overstated the value of the generic drug budesonide. In August 2019, the Court granted Impax’s motion to dismiss Plaintiff’s subsequent second amended complaint in its entirety. Plaintiff appealed to the United States Court of Appeals for the Ninth Circuit, and on January 11, 2021, the Ninth Circuit issued an unpublished opinion affirming in part and reversing in part the District Court’s decision. Impax subsequently filed a motion for rehearing with the Ninth Circuit, and Plaintiff filed a motion to intervene seeking to add Sheet Metal Workers’ Pension Fund of Southern California, Arizona and Nevada (“Sheet Metal Workers”) as an additional named Plaintiff The Ninth Circuit denied the motions, and on April 1, 2021, the case was remanded to the District Court. On April 19, 2021, the Company filed a motion to dismiss the remaining claims and an opposition to Sheet Metal Workers’ renewed motion to intervene.

On December 18, 2019, Cambridge Retirement System filed a putative class action complaint in the Superior Court of New Jersey, Somerset County against the Company and certain current or former officers alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (Cambridge Retirement System v. Amneal Pharmaceuticals, Inc., et al., No. SOM-L-1701-19). Plaintiffs allege that the May 7, 2018 amended registration statement and prospectus issued in connection with the Amneal/Impax business combination was materially false and/or misleading because it failed to disclose that Amneal allegedly engaged in anticompetitive conduct to fix generic drug prices. Plaintiff filed a motion for class certification on October 30, 2020, and in response to Amneal’s opposition, Plaintiffs amended their complaint to include similar allegations with regard to a November, 2017 registration statement issued by an Impax-related entity. The Court has set a briefing schedule for Amneal’s motion to dismiss the Amended Complaint.
United States Department of Justice / Drug Enforcement Administration Subpoenas

On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the "USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered tolling agreements with the USAO through approximately May 12, 2021. It is not possible to determine the exact outcome of these investigations at this time.

On March 14, 2019, Amneal received a subpoena (the “Subpoena”) from an Assistant U.S. Attorney (“AUSA”) for the Southern District of Florida. The Subpoena requests information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the Subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation.

Ranitidine Litigation

The Company and its affiliates have been named as defendants, along with numerous other pharmaceutical manufacturers, wholesale distributors, and retail pharmacy chains, in In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), pending in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. Consolidated groups of (a) personal injury plaintiffs, (b) economic loss/medical monitoring class action plaintiffs, and (c) third-party payor plaintiffs have each filed master complaints against brand and generic pharmaceutical manufacturers, distributors, retailers, and repackagers of ranitidine-containing products. The Company or its affiliates have been named in the three master complaints and approximately 190 personal injury short form complaints. On December 31, 2020, the Court dismissed in full the three master complaints against the generic manufacturers, including the Company and its affiliates, with leave to file amended complaints on certain claims relating to manufacturing, storage and transportation. Plaintiffs filed amended complaints on February 8 and February 22, 2021, and Defendants have filed various motions to dismiss the amended complaints. Discovery remains ongoing.
On November 12, 2020, Amneal Pharmaceuticals LLC was named in a lawsuit filed in state court in Baltimore, Maryland, on behalf of the Mayor and City Council of Baltimore, alleging claims of public nuisance, negligence, and violations of state consumer protection laws against brand and generic manufacturers and store-brand distributors of Zantac®/ranitidine. Plaintiffs seek unspecified compensatory and punitive damages, as well as civil penalties and injunctive relief. Defendants removed the case to federal court, and on January 6, 2021, a conditional transfer order to the MDL was issued. On April 2, 2021, the MDL Court remanded the case to state court. On February 5, 2021, the MDL similarly remanded a New Mexico state case that also had been removed to federal court.

Metformin Litigation

Amneal and AvKARE, Inc. were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey (“D.N.J.”), consolidated as In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH). The lawsuits all allege that defendants made and sold to putative class members generic metformin products that were “adulterated” or “contaminated” with NDMA.

An economic loss complaint filed on behalf of consumers and third-party payors who purchased or paid or made reimbursements for metformin alleges that plaintiffs suffered economic losses in connection with their purchases or reimbursements due to the purported contamination. Medical monitoring class action complaints filed on behalf of consumers who consumed allegedly contaminated metformin allege “cellular damage, genetic harm, and/or are at an increased risk of developing cancer", and seek medical monitoring, including evaluation and treatment.

Xyrem® (sodium oxybate) Antitrust Litigation
Amneal has been named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several putative class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with settling patent litigation related to Xyrem®. Plaintiffs seek unspecified monetary damages and penalties as well as equitable relief, including disgorgement and restitution. On December 16, 2020, the JPML transferred the actions to the United States District Court for the Northern District of California for consolidated pretrial proceedings.
v3.21.1
Segment Information
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has three reportable segments: Generics, Specialty, and AvKARE.
Generics
Generics develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals across a broad range of therapeutic categories. Generics’ retail and institutional portfolio contains approximately 250 product families, many of which represent difficult-to-manufacture products or products that have a high barrier-to-entry, such as oncologics, anti-infectives and supportive care products for healthcare providers.
Specialty
Specialty delivers proprietary medicines to the U.S. market. The Company offers a growing portfolio in core therapeutic categories including central nervous system disorders, endocrinology, parasitic infections and other therapeutic areas. The Company's specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Specialty also has a number of product candidates that are in varying stages of development.
AvKARE
AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs.  AvKARE is also a wholesale distributor of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, as well as medical and surgical products.  AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and
institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.
The Company’s chief operating decision maker evaluates the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in "Corporate and Other." The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker.
The tables below present segment information reconciled to total Company financial results, with segment operating income (loss) including gross profit less direct selling, general and administrative expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Three Months Ended March 31, 2021
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$312,508 $95,931 $84,666 $— $493,105 
Cost of goods sold185,298 48,198 68,047 — 301,543 
Gross profit127,210 47,733 16,619 — 191,562 
Selling, general and administrative18,762 19,881 13,704 38,379 90,726 
Research and development36,117 12,065 — — 48,182 
Intellectual property legal development expenses3,582 — — — 3,582 
Acquisition, transaction-related and integration expenses— — 931 1,871 2,802 
Restructuring and other charges80 — — 283 363 
Operating income (loss)$68,669 $15,787 $1,984 $(40,533)$45,907 

Three Months Ended March 31, 2020
Generics (1)
Specialty
AvKARE (1,2)
Corporate
and Other
Total
Company
Net revenue$352,586 $87,977 $57,970 $— $498,533 
Cost of goods sold218,865 47,818 46,895 — 313,578 
Cost of goods sold impairment charges1,456 — — 1,456 
Gross profit132,265 40,159 11,075 — 183,499 
Selling, general and administrative16,623 20,942 10,788 29,623 77,976 
Research and development29,034 7,345 — — 36,379 
In-process research and development impairment charges960 — — — 960 
Intellectual property legal development expenses1,265 — — 1,270 
Acquisition, transaction-related and integration expenses— — — 2,575 2,575 
Charges related to legal matters, net2,500 2,000 — — 4,500 
Restructuring and other charges46 — — 2,002 2,048 
Operating income (loss)$81,837 $9,867 $287 $(34,200)$57,791 
(1)Operating results for the sale of Amneal products by AvKARE are included in Generics.
(2)The AvKARE segment consists of the businesses acquired in the Acquisitions on January 31, 2020. Operating results for the three months ended March 31, 2020 represent two months of activity.
v3.21.1
Related Party Transactions
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The Company has various business agreements with certain third-party companies in which there is some common ownership and/or management between those entities, on the one hand, and the Company, on the other hand. The Company has no direct ownership or management in any of such related party companies. The related party relationships that generated income and/ or expense in the respective reporting periods are described below.
Financing Lease - Related Party
The Company has a financing lease for two buildings located in Long Island, New York, which are used as an integrated manufacturing and office facility. The Company leased these buildings from LAX Hotel, LLC from 2012 until January 2021. During 2020, LAX Hotel, LLC was controlled by a member of the Amneal Group, who also serves as observer on the Company's Board of Directors. As a result, this lease had been historically accounted for as a related party financing lease.
During January 2021, LAX Hotel, LLC sold its interests in the leased buildings to an unrelated third party. Therefore, this lease is no longer a related party transaction, and the corresponding financing lease right-of-use asset and liability have been reclassified in the consolidated balance sheet as of March 31, 2021 to reflect this change. For the three months ended March 31, 2021, lease costs and interest expense related to this lease were $0.2 million and $0.4 million, respectively. For the three months ended March 31, 2020, lease costs and interest expense were each approximately $1 million.
For annual payments required under the terms of the non-cancelable lease agreement over the next five years and thereafter, refer to Note 12. Leases in the Company’s 2020 Annual Report on Form 10-K.
Kanan, LLC
Kanan, LLC ("Kanan") is a real estate company which owns Amneal’s manufacturing facilities located at 65 Readington Road, Branchburg, New Jersey, 131 Chambers Brook Road, Branchburg, New Jersey and 1 New England Avenue, Piscataway, New Jersey. Certain executive officers of the Company beneficially own, through certain revocable trusts, equity securities of Kanan. In addition, they serve on the management team of Kanan. Amneal leases these facilities from Kanan under two separate triple-net lease agreements that expire in 2027 and 2031, respectively, at an annual rental cost of approximately $2 million combined, subject to CPI rent escalation adjustments as provided in the lease agreements. Rent expense paid to Kanan for both the three months ended March 31, 2021 and 2020 was $0.5 million.
Asana Biosciences, LLC
Asana Biosciences, LLC (“Asana”) is an early stage drug discovery and research and development company focusing on several therapeutic areas, including oncology, pain and inflammation. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Asana. In addition, they serve on the management team of Asana. From time to time, Amneal provides research and development services to Asana under a development and manufacturing agreement. There was no income for the three months ended March 31, 2021 or 2020. As of March 31, 2021 and December 31, 2020, there was no amount due from Asana for research and development related services.
Industrial Real Estate Holdings NY, LLC and Sutaria Family Realty, LLC
Industrial Real Estate Holdings NY, LLC ("IRE") is a real estate management entity, which was the sub-landlord of Amneal’s leased manufacturing facility located at 75 Adams Avenue, Hauppauge, New York. IRE is controlled by a member of the Amneal Group, who also serves as an observer on the Company's Board of Directors. Effective June 1, 2020, the lease was assigned to the Company with the consent of the landlord, Sutaria Family Realty, LLC, which is also a related party because a member of Company management is a beneficial owner. Concurrently with the assignment of the lease, the Company exercised a renewal option for $0.1 million to extend the lease by 5 years until March 31, 2026. Monthly rent payments are $0.1 million and increase by 3% annually. Rent paid to the related parties for both of the three months ended March 31, 2021 and 2020 was $0.3 million.
Kashiv BioSciences, LLC
Kashiv is an independent contract development organization focused primarily on the development of 505(b)(2) NDA products. Amneal has various business agreements with Kashiv. Certain executive officers of the Company beneficially own, directly and
through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Kashiv. In addition, they serve as managers of Kashiv.
On January 11, 2021, the Company and Kashiv entered into a definitive agreement for Amneal to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), a subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs. The acquisition closed on April 2, 2021. Certain of the contracts between Amneal and Kashiv were acquired in this transaction and have become transactions among Amneal's consolidated subsidiaries subsequent to the transaction closing. Refer to Note 3. Acquisitions and Divestitures for further details on the KSP acquisition.
Agreements with Kashiv Not Affected by the Acquisition of KSP
The parties entered into a lease for parking spaces in Piscataway, NJ. The total amount of expense paid to Kashiv from this agreement for each of the three months ended March 31, 2021 and 2020 was less than $0.1 million.
Amneal also has various consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. The total expenses associated with these arrangements for the three months ended March 31, 2021 was less than $0.1 million (none for the three months ended March 31, 2020).
The table below includes the terms and expenses recognized for each of the product specific contracts with Kashiv.
Amounts in millions
Research and development expenses for three months ended March 31,
ProductsAgreement Date20212020
Filgrastim and PEG-Filgrastim (1)
October 2017$— $— 
Ganirelix Acetate and Cetrorelix acetate (2)
August 2020$$— 
(1) Kashiv granted Amneal an exclusive license, under its New Drug Application, to distribute and sell two bio-similar products in the U.S. Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling and pricing activities. The term of the agreement is 10 years from the respective product’s launch date. The agreement provides for potential future milestone payments to Kashiv of (i) up to $21 million relating to regulatory approval, (ii) up to $43 million for successful delivery of commercial launch inventory, (iii) between $20 million and $50 million relating to number of competitors at launch for one product, and (iv) between $15 million and $68 million for the achievement of cumulative net sales for both products. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval, launch activities and commercial sales volume objectives. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.
(2) Amneal and Kashiv entered into a product development agreement for the development and commercialization of two generic peptide products, Ganirelix Acetate and Cetrorelix Acetate. Under the agreement, the intellectual property and ANDA for these products are owned by Amneal, and Kashiv is to receive a profit share for all sales of the products made by Amneal. In connection with the agreement, Amneal made an upfront payment for $1 million during August 2020. The agreement also provides for potential future milestone payments to Kashiv of (i) up to $2 million relating to development milestones, and (ii) up to $0.3 million relating to regulatory filings. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filings. In addition, Amneal is to pay $3 million of development fees to Kashiv as the development work is completed.
Agreements with Kashiv Included in the Acquisition of KSP
The following contracts previously between Amneal and Kashiv were acquired with KSP and have become transactions among Amneal's consolidated subsidiaries subsequent to the transaction closing on April 2, 2021. The disclosures below relate to the historical agreements as related party transactions through March 31, 2021.
Amneal has various development and commercialization arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. The total reimbursable expenses associated with these arrangements for the three months ended March 31, 2021 and 2020, respectively, was $0.1 million and $0.2 million.  Kashiv receives a percentage of net profits with respect to Amneal’s sales of these products. The total profit share paid to Kashiv for each of the three months ended March 31, 2021 and 2020 was $3 million.  
On February 20, 2020, the Company and Kashiv entered into a master services agreement covering certain services that Kashiv provides the Company for commercial product support related to EluRyng and other products, including Ranitidine and Nitrofurantoin. For each of the three months ended March 31, 2021 and 2020, the Company recorded $1 million to cost of goods sold to compensate Kashiv for services performed.
The following table includes the expenses recognized for each of the product specific contracts with Kashiv prior to the acquisition of these contracts as part of the KSP transaction.
Amounts in millions
Research and development expenses for three months ended March 31,
ProductsAgreement Date20212020
Levothyroxine Sodium(1)
June 2019$— $— 
K127 (2)
November 2019$$
Posaconazole (3)
May 2020$— $— 
(1) Pursuant to a product development agreement, Amneal and Kashiv agreed to collaborate on the development and commercialization of Levothyroxine Sodium. Under the agreement, the intellectual property and ANDA for this product is owned by Amneal, and Kashiv is to receive a profit share for all sales of the product made by Amneal. Amneal is precluded from selling the product made by Kashiv during the term of the license and supply agreement with Jerome Stevens Pharmaceuticals (refer to Note 5. Alliance and Collaboration, in the Company's 2020 Annual Report on Form 10-K for additional details). Under the terms of the amended agreement with Kashiv, Amneal paid $2 million in July 2019 and may be required to pay up to an additional $18 million upon certain regulatory milestones being met.
(2) Amneal and Kashiv have a licensing agreement for the development and commercialization of Kashiv’s orphan drug K127 (Pyridostigmine) for the treatment of Myasthenia Gravis. Under the terms of the agreement, Kashiv will be responsible for all development and clinical work required to secure Food and Drug Administration approval, and Amneal will be responsible for filing the NDA and commercializing the product. The Company made an upfront payment of approximately $2 million to Kashiv in December 2019, and Kashiv is eligible to receive development and regulatory milestones totaling approximately $17 million. Kashiv is also eligible to receive tiered royalties from the low double-digits to mid-teens on net sales of K127.
(3) Amneal and Kashiv have a product development agreement for the development and commercialization of Posaconazole. In connection with the agreement, Amneal paid an upfront amount of $0.3 million in May 2020 for execution of the agreement. The agreement also provides for potential future milestone payments to Kashiv of (i) up to $0.8 million relating to development milestones, (ii) up to $0.3 million relating to regulatory approval, and (iii) up to $1 million for the achievement of cumulative net sales. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval and commercial sales volume objectives.
At March 31, 2021 and December 31, 2020, payables of approximately $8 million and $5 million, respectively, were due to Kashiv. Additionally, as of December 31, 2020 a receivable of $0.1 million was due from Kashiv.
PharmaSophia, LLC
PharmaSophia, LLC ("PharmaSophia") is a joint venture formed by Nava Pharma, LLC ("Nava") and Oakwood Laboratories, LLC for the purpose of developing certain products. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Nava. Nava beneficially owns 50% of the outstanding equity securities of PharmaSophia. In addition, these executive officers also serve on the management team of Nava. Currently PharmaSophia is actively developing one injectable product. PharmaSophia and Nava are parties to a research and development agreement pursuant to which Nava provides research and development
services to PharmaSophia. Nava subcontracted this obligation to Amneal, entering into a subcontract research and development services agreement pursuant to which Amneal provides research and development services to Nava in connection with the products being developed by PharmaSophia. The total amount of income earned from these agreements for the three months ended March 31, 2021 and 2020 was $0.3 million and $0.2 million, respectively. At March 31, 2021 and December 31, 2020 receivables of $1 million and $0.8 million, respectively, were due from the related party.
Fosun International Limited
Fosun International Limited (“Fosun”) is a Chinese international conglomerate and investment company that is a shareholder of the Company. On June 6, 2019, the Company entered into a license and supply agreement with a subsidiary of Fosun, which is a Chinese pharmaceutical company. Under the terms of the agreement, the Company will hold the imported drug license required for pharmaceutical products manufactured outside of China and will supply Fosun with finished, packaged products for Fosun to then sell in the China market. Fosun will be responsible for obtaining regulatory approval in China and for shipping the product from Amneal’s facility to Fosun’s customers in China. In consideration for access to the Company's U.S. regulatory filings to support its China regulatory filings and for the supply of product, Fosun paid the Company a $1 million non-refundable fee, net of tax, in July 2019 and will be required to pay the Company $0.3 million for each of eight products upon the first commercial sale of each in China in addition to a supply price and a profit share. The Company has not recognized any revenue from this agreement.
Apace KY, LLC d/b/a Apace Packaging LLC
Apace KY, LLC d/b/a Apace Packaging LLC (“Apace”) provides packaging solutions pursuant to an exclusive packaging agreement. Apace markets its services which include bottling and blistering for the pharmaceutical industry. A member of Company management beneficially owns outstanding equity securities of Apace. The total amount of expenses from this arrangement for each of the three months ended March 31, 2021 and 2020 was $2 million. At both March 31, 2021 and December 31, 2020, payables of $1.0 million were due to the related party for packaging services. Additionally, at March 31, 2021 and December 31, 2020, receivables of $0.1 million and $0.5 million, respectively, was due from the related party for a product recall.
Tracy Properties LLC
R&S leases operating facilities, office and warehouse space from Tracy Properties LLC ("Tracy"). A member of Company management beneficially owns outstanding equity securities of Tracy. The total amount of expenses from this arrangement for both of the three months ended March 31, 2021 and 2020 was $0.1 million.
AzaTech Pharma LLC
R&S purchases inventory from AzaTech Pharma LLC ("AzaTech") for resale. A member of Company management beneficially owns outstanding equity securities of AzaTech. The total amount of purchases from this arrangement for the three months ended March 31, 2021 and 2020 was $1 million and $0.8 million, respectively. At March 31, 2021 and December 31, 2020, payables of approximately $0.7 million and $1 million, respectively, were due to AzaTech for inventory purchases.
AvPROP, LLC
AvKARE LLC leases its operating facilities from AvPROP, LLC ("AvPROP"). A member of Company management beneficially owns outstanding equity securities of AvPROP. Rent expense from this arrangement for both of the three months ended March 31, 2021 and 2020 was $0.1 million.
Tarsadia Investments, LLC
Tarsadia Investments, LLC (“Tarsadia”) is a private investment firm that provides financial services and is a significant shareholder of the Company. A member of Amneal Group, and an observer to the Board, is the Chairman and Founder of Tarsadia Investments. Another member of the Amneal Group, and a member of the Board, is a Managing Director of Tarsadia Investments. Tarsadia offers capital and strategic support for companies with substantial growth potential primarily in the healthcare, financial services, real estate, and clean technology sectors.  The Company entered into an agreement in which Tarsadia will provide financial consulting services. The services are not expected to have a material impact to the Company’s financial statements.
Avtar Investments, LLC
Avtar Investments, LLC ("Avtar") is a private investment firm. Members of Company management beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Avtar. During April 2020, the Company entered into an agreement in which Avtar will provide consulting services. The total amount of consulting expense incurred for the three months ended March 31, 2021 was $0.1 million (none in the three months ended March 31, 2020). As of both March 31, 2021 and December 31, 2020, less than $0.1 million was due to Avtar.
Zep Inc.
Zep Inc. ("Zep") is a producer, and distributor of maintenance and cleaning solutions for retail, food & beverage, industrial & institutional, and vehicle care customers. An executive officer of the Company serves as a director of Zep. During May 2020, AvKARE entered into an agreement to supply cleaning products to Zep. There was no revenue derived from this related party agreement for three months ended March 31, 2021 or 2020. As of December 31, 2020, $0.1 million was recorded in related party receivables (no related party receivable as of March 31, 2021).
Tax Distributions
Under the terms of its limited liability company agreement, Amneal is obligated to make tax distributions to its members, which are also holders of non-controlling interests in the Company. For further details, refer to Note 17. Stockholders' Equity and Redeemable Non-Controlling Interests.
Additionally, under the terms of the limited liability company agreement between the Company and the holders of the Rondo Class B Units, Rondo is obligated to make tax distributions to those holders, subject to certain limitations as defined in the Rondo Credit Facility. For further details, refer to Note 17. Stockholders' Equity and Redeemable Non-Controlling Interests.
Notes Payable – Related Party
The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest in Rondo (“Rondo Class B Units”).  Certain holders of the Rondo Class B Units are also holders of the Sellers Notes and the Short-Term Sellers Note.  For additional information, refer to Note 3. Acquisitions and Divestitures.
v3.21.1
Goodwill and Intangible Assets
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows (in thousands):
March 31,
2021
December 31,
2020
Balance, beginning of period$522,814 $419,504 
Goodwill acquired during the period— 103,679 
Currency translation(56)(369)
Balance, end of period$522,758 $522,814 
As of both March 31, 2021 and December 31, 2020, $361 million, $92 million, and $70 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. Refer to Note 3. Acquisitions and Divestitures for additional information about the Acquisitions.
Intangible assets at March 31, 2021 and December 31, 2020 were comprised of the following (in thousands):
March 31, 2021December 31, 2020
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights8.8$1,149,245 $(360,174)$789,071 $1,153,096 $(328,587)$824,509 
Other intangible assets5.5133,800 (39,312)94,488 133,800 (33,078)100,722 
Subtotal$1,283,045 $(399,486)$883,559 $1,286,896 $(361,665)$925,231 
In-process research and development
379,395 — 379,395 379,395 — 379,395 
Total intangible assets$1,662,440 $(399,486)$1,262,954 $1,666,291 $(361,665)$1,304,626 

The Company evaluated assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. For the three months ended March 31, 2021, the Company did not recognize any intangible asset impairment charges.
The impairment charges for the three months ended March 31, 2020 were primarily related to two currently marketed products and two in-process research and development (“IPR&D”) products.  For the currently marketed products, two products experienced significant price erosion during 2020, without an offsetting increase in customer demand, resulting in significantly lower than expected future cash flows and negative margins. The IPR&D charges are associated with two products, one of which experienced a delay in its estimated launch date and the other of which was canceled due to the withdrawal of our development partner.
During the three months ended March 31, 2020, the Company recognized $131 million of intangible assets associated with the Acquisitions, of which all are classified in other intangible assets in the table above.  These intangible assets consist of government licenses, government contracts, national contracts, customer relationships and a trade name and are amortized to selling, general, and administrative over their estimated useful lives.  Refer to Note 3. Acquisitions and Divestitures for additional information.
Amortization expense related to intangible assets recognized is as follows (in thousands):
Three Months Ended March 31,
20212020
Amortization$41,672 $42,576 
The following table presents future amortization expense for the next five years and thereafter, excluding $379 million of IPR&D intangible assets (in thousands):
Future
Amortization
Remainder of 2021$125,091 
2022155,162 
2023143,395 
2024136,910 
202597,937 
Thereafter225,064 
Total$883,559 
v3.21.1
Stockholders’ Equity and Redeemable Non-Controlling Interests
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Stockholders’ Equity and Redeemable Non-Controlling Interests Stockholders’ Equity and Redeemable Non-Controlling Interests
Non-Controlling Interests
Under the terms of Amneal's limited liability company agreement, as amended, Amneal is obligated to make tax distributions to its members. For the three months ended March 31, 2021, a tax distribution of $9 million was recorded as a reduction of non-controlling interests (none for the three months ended March 31, 2020), and included as related-party payables as of March 31, 2021, which was paid in full during April 2021.

Redeemable Non-Controlling Interests
As discussed in Note 3. Acquisitions and Divestitures, the Company acquired a 65.1% interest in Rondo on January 31, 2020.  The sellers of AvKARE, LLC and R&S hold the remaining 34.9% interest as Rondo Class B Units.  Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met.  Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right.  The Rondo Class B Units are also redeemable by the holders upon a change in control.
Since the redemption of the Rondo Class B Units is outside of the Company's control, the units have been presented outside of stockholders' equity as redeemable non-controlling interests. Upon closing of the Acquisitions on January 31, 2020, the redeemable non-controlling interests were recorded as a component of the fair value of consideration transferred at an estimated preliminary fair value of $11 million. The fair value of the redeemable non-controlling interests was estimated using the Monte-Carlo simulation approach under the option pricing framework, which considers the redemption rights of both the Company and the holders of the Rondo Class B Units.
The Company will attribute 34.9% of the net income of Rondo to the redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption probable. For the three months ended March 31, 2021, a tax distribution of $0.5 million was recorded as a reduction of redeemable non-controlling interests (none for the three months ended March 31, 2020) and included as a related-party payable as of March 31, 2021.
Changes in Accumulated Other Comprehensive Loss by Component (in thousands):
Foreign
currency
translation
adjustment
Unrealized
gain (loss) on cash
flow hedge, net
of tax
Accumulated
other
comprehensive
loss
Balance December 31, 2019$(7,832)$7,764 $(68)
Other comprehensive loss before reclassification(6,643)(34,560)(41,203)
Reallocation of ownership interests(22)(25)(47)
Balance December 31, 2020(14,497)(26,821)(41,318)
Other comprehensive loss before reclassification(3,139)10,243 7,104 
Reallocation of ownership interests(52)(95)(147)
Balance March 31, 2021$(17,688)$(16,673)$(34,361)
v3.21.1
Subsequent Events
3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Kashiv Specialty Pharmaceuticals Acquisition
On January 11, 2021, the Company and Kashiv (a related party, see Note 16. Related Party Transactions) entered into a definitive agreement for Amneal to acquire a 98% interest in KSP, a subsidiary of Kashiv focused on the development of innovative drug delivery platforms, novel 505(b)(2) drugs, and complex generics. Refer to Note 3. Acquisitions and Divestitures for additional information.

Class B-1 Common Stock
On May 5, 2021, the shareholders of the Company approved an amended and restated certificate of incorporation which retired shares of class B-1 common stock.
v3.21.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited consolidated financial statements, which are prepared in accordance with generally accepted accounting principles in the United States of America, should be read in conjunction with Amneal’s annual audited financial statements for the year ended December 31, 2020 included in the Company’s 2020 Annual Report on Form 10-K. Certain information and footnote disclosures normally included in annual financial statements have been omitted from the accompanying unaudited consolidated financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of March 31, 2021, cash flows for the three months ended March 31, 2021 and 2020 and the results of its operations, its comprehensive income and its changes in stockholders' equity for the three months ended March 31, 2021 and 2020. The consolidated balance sheet data at December 31, 2020 was derived from the Company's audited annual financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America.
The accounting policies of the Company are set forth in Note 2. Summary of Significant Accounting Policies contained in the Company’s 2020 Annual Report on Form 10-K. The following significant accounting policy has been updated to include the Company's accounting for foreign currency transactions that are of a long-term investment in nature.
Foreign Currencies
Foreign Currencies

The Company has operations in the U.S., India, Ireland, and other international jurisdictions. Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in accumulated other comprehensive loss.
Use of Estimates
Use of Estimates
The preparation of financial statements requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of
expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform.  These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU 2020-04. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
Reclassification
Reclassification

Prior period balances related to (i) financing lease right-of-use assets of $10 million formerly included in other assets, (ii) current portion of financing lease liabilities of $2 million formerly included in accounts payable and accrued expenses, and (iii) long-term lease liabilities of $2 million formerly included in other long-term liabilities as of December 31, 2020 have been reclassified to their respective balance sheet captions to conform to the current period presentation in the consolidated balance sheets.
Performance Obligations The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
v3.21.1
Acquisitions and Divestitures (Tables)
3 Months Ended
Mar. 31, 2021
Business Acquisition [Line Items]  
Schedule of Business Acquisition Pro Forma Data
The unaudited pro forma combined results of operations for the three months ended March 31, 2020 (assuming the closing of the Acquisitions occurred on January 1, 2020) are as follows (in thousands):
Net revenue$525,303 
Net income$122,521 
Net income attributable to Amneal Pharmaceuticals, Inc.$115,388 
AvKARE and R&S Acquisitions  
Business Acquisition [Line Items]  
Schedule of Purchase Price
The purchase price was calculated as follows (in thousands):
Cash$254,000 
Sellers Notes (1)
35,033 
Settlement of Amneal trade accounts receivable from R&S (2)
6,855 
Short-Term Seller Note (3)
1,000 
Working capital adjustment (4)
(2,640)
Fair value consideration transferred$294,248 
(1)In accordance with ASC 805, Business Combinations, all consideration transferred was measured at its acquisition-date fair value. The Sellers Notes are stated at the fair value estimate of $35 million, which is the $44 million aggregate principal amount less a $9 million discount.  The fair value of the Sellers Notes was estimated using the Monte-Carlo simulation approach under the option pricing framework.
(2)Represents trade accounts receivable from R&S that was effectively settled upon closing of the Acquisitions.
(3)Represents the principal amount due on the Short-Term Seller Note, which approximates fair value. The entire Short-Term Seller Note was repaid in February 2021.
(4)Represents a working capital adjustment pursuant to the terms of the purchase agreement. The entire amount was received in cash by the Company in September 2020.
Schedule of Purchase Price Allocation
The following is a summary of the purchase price allocation for the Acquisitions (in thousands):
Final Fair Values as of
January 31, 2020
Trade accounts receivable, net$46,702 
Inventories71,908 
Prepaid expenses and other current assets11,316 
Related party receivables61 
Property, plant and equipment5,278 
Goodwill103,679 
Intangible assets, net130,800 
Operating lease right-of-use assets - related party5,544 
Total assets acquired375,288 
Accounts payable and accrued expenses62,489 
Related party payables1,532 
Operating lease liabilities - related party5,544 
Total liabilities assumed69,565 
Redeemable non-controlling interests11,475 
Fair value of consideration transferred$294,248 
Schedule of Acquired Intangible Assets
The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands):

Fair Values
Weighted-Average
Useful Life
Government licenses$66,700 7 years
Government contracts22,000 4 years
National contracts28,600 5 years
Customer relationships13,000 10 years
Trade name500 6 years
$130,800 
v3.21.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregated Revenue
The Company's significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the three months ended March 31, 2021 and 2020 are set forth below (in thousands):
Three Months Ended March 31,
20212020
Generics
Anti-Infective$5,913 $13,253 
Hormonal106,703 87,481 
Antiviral (1)
(7,941)15,824 
Central Nervous System96,291 101,575 
Cardiovascular System35,311 29,679 
Gastroenterology19,458 23,536 
Oncology19,030 15,966 
Metabolic Disease/Endocrine6,557 17,229 
Respiratory8,178 10,067 
Dermatology12,878 15,245 
Other therapeutic classes9,731 21,746 
International and other399 985 
Total Generics net revenue312,508 352,586 
Specialty
Hormonal/Metabolic16,796 14,227 
Central Nervous System67,711 68,311 
Other therapeutic classes11,424 5,439 
Total Specialty net revenue95,931 87,977 
AvKARE (2)
Distribution45,499 31,586 
Government Label31,072 21,378 
Institutional5,179 3,413 
Other2,916 1,593 
Total AvKARE net revenue84,666 57,970 
Total net revenue$493,105 $498,533 
(1) Antiviral revenue for the three months ended March 31, 2021 decreased from the prior year, primarily due to a $23 million decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels due to decreased influenza activity during the COVID-19 pandemic.
(2) The AvKARE segment consists of the businesses acquired in the Acquisitions on January 31, 2020. Net revenue for the three months ended March 31, 2020 represent two months of activity.
Schedule of Major Categories of Sales-Related Deductions
A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2021 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2020$628,804 $22,690 $174,984 $131,088 
Provision related to sales recorded in the period727,258 25,048 24,786 28,770 
Credits/payments issued during the period(838,304)(25,402)(25,758)(26,852)
Balance at March 31, 2021$517,758 $22,336 $174,012 $133,006 
v3.21.1
Earnings per Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings (Loss) Per Share, Basic and Diluted
The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per share of class A common stock (in thousands, except per share amounts):
Three Months Ended
March 31,
20212020
Numerator:
Net income attributable to Amneal Pharmaceuticals, Inc.$6,706 $115,067 
Denominator:
Weighted-average shares outstanding - basic148,013 147,180 
Effect of dilutive securities:
Stock options792 230 
Restricted stock units2,415 546 
Weighted-average shares outstanding - diluted
151,220 147,956 
Net earnings per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:
Basic$0.05 $0.78 
Diluted$0.04 $0.78 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents potentially dilutive securities excluded from the computations of diluted earnings per share of class A common stock (in thousands):
Three Months Ended
March 31,
20212020
Stock options
347 
(1)
683 
(1)
Performance stock units
5,124 
(2)
3,054 
(2)
Shares of class B common stock152,117 
(3)
152,117 
(3)
(1)Excluded from the computation of diluted earnings per share of class A common stock because the exercise price of the stock options exceeded the average market price of the class A common stock during the period (out-of-the-money).
(2)Excluded from the computation of diluted earnings per share of class A common stock because the performance vesting conditions were not met for the three months ended March 31, 2021 and 2020.
(3)Shares of class B common stock are considered potentially dilutive shares of class A common stock. Shares of class B common stock have been excluded from the computations of diluted earnings per common share because the effect of their inclusion would have been anti-dilutive under the if-converted method.
v3.21.1
Trade Accounts Receivable, Net (Tables)
3 Months Ended
Mar. 31, 2021
Receivables [Abstract]  
Schedule of Trade Accounts Receivable, Net
Trade accounts receivable, net is comprised of the following (in thousands):
March 31,
2021
December 31,
2020
Gross accounts receivable$1,072,138 $1,291,785 
Allowance for credit losses(1,444)(1,396)
Contract charge-backs and sales volume allowances(517,758)(628,804)
Cash discount allowances(22,336)(22,690)
Subtotal(541,538)(652,890)
Trade accounts receivable, net$530,600 $638,895 
v3.21.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Components of Inventories, Net of Reserves
Inventories are comprised of the following (in thousands):
March 31,
2021
December 31,
2020
Raw materials
$205,874 $209,180 
Work in process
51,633 40,937 
Finished goods
239,501 240,532 
Total inventories$497,008 $490,649 
v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
Fair Value Measurement Based on
March 31, 2021TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Liabilities
Interest rate swap (1)
$33,131 $— $33,131 $— 
Deferred compensation plan liabilities (2)
$14,500 $— $14,500 $— 
December 31, 2020
Liabilities
Interest rate swap (1)
$53,903 — $53,903 — 
Deferred compensation plan liabilities (2)
$14,007 — $14,007 — 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 12. Financial Instruments for information on the Company's interest rate swap.
(2)As of March 31, 2021, deferred compensation plan liabilities of $2 million and $13 million were recorded in current and non-current liabilities, respectively. As of December 31, 2020, deferred compensation plan liabilities of $2 million and $12 million were recorded in current and non-current liabilities, respectively. These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants.
v3.21.1
Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
March 31, 2021December 31, 2020
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther long-term liabilities$33,131 Other long-term liabilities$53,903 
v3.21.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The tables below present segment information reconciled to total Company financial results, with segment operating income (loss) including gross profit less direct selling, general and administrative expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Three Months Ended March 31, 2021
Generics (1)
Specialty
AvKARE (1)
Corporate
and Other
Total
Company
Net revenue$312,508 $95,931 $84,666 $— $493,105 
Cost of goods sold185,298 48,198 68,047 — 301,543 
Gross profit127,210 47,733 16,619 — 191,562 
Selling, general and administrative18,762 19,881 13,704 38,379 90,726 
Research and development36,117 12,065 — — 48,182 
Intellectual property legal development expenses3,582 — — — 3,582 
Acquisition, transaction-related and integration expenses— — 931 1,871 2,802 
Restructuring and other charges80 — — 283 363 
Operating income (loss)$68,669 $15,787 $1,984 $(40,533)$45,907 

Three Months Ended March 31, 2020
Generics (1)
Specialty
AvKARE (1,2)
Corporate
and Other
Total
Company
Net revenue$352,586 $87,977 $57,970 $— $498,533 
Cost of goods sold218,865 47,818 46,895 — 313,578 
Cost of goods sold impairment charges1,456 — — 1,456 
Gross profit132,265 40,159 11,075 — 183,499 
Selling, general and administrative16,623 20,942 10,788 29,623 77,976 
Research and development29,034 7,345 — — 36,379 
In-process research and development impairment charges960 — — — 960 
Intellectual property legal development expenses1,265 — — 1,270 
Acquisition, transaction-related and integration expenses— — — 2,575 2,575 
Charges related to legal matters, net2,500 2,000 — — 4,500 
Restructuring and other charges46 — — 2,002 2,048 
Operating income (loss)$81,837 $9,867 $287 $(34,200)$57,791 
(1)Operating results for the sale of Amneal products by AvKARE are included in Generics.
(2)The AvKARE segment consists of the businesses acquired in the Acquisitions on January 31, 2020. Operating results for the three months ended March 31, 2020 represent two months of activity.
v3.21.1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The table below includes the terms and expenses recognized for each of the product specific contracts with Kashiv.
Amounts in millions
Research and development expenses for three months ended March 31,
ProductsAgreement Date20212020
Filgrastim and PEG-Filgrastim (1)
October 2017$— $— 
Ganirelix Acetate and Cetrorelix acetate (2)
August 2020$$— 
(1) Kashiv granted Amneal an exclusive license, under its New Drug Application, to distribute and sell two bio-similar products in the U.S. Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling and pricing activities. The term of the agreement is 10 years from the respective product’s launch date. The agreement provides for potential future milestone payments to Kashiv of (i) up to $21 million relating to regulatory approval, (ii) up to $43 million for successful delivery of commercial launch inventory, (iii) between $20 million and $50 million relating to number of competitors at launch for one product, and (iv) between $15 million and $68 million for the achievement of cumulative net sales for both products. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval, launch activities and commercial sales volume objectives. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.
(2) Amneal and Kashiv entered into a product development agreement for the development and commercialization of two generic peptide products, Ganirelix Acetate and Cetrorelix Acetate. Under the agreement, the intellectual property and ANDA for these products are owned by Amneal, and Kashiv is to receive a profit share for all sales of the products made by Amneal. In connection with the agreement, Amneal made an upfront payment for $1 million during August 2020. The agreement also provides for potential future milestone payments to Kashiv of (i) up to $2 million relating to development milestones, and (ii) up to $0.3 million relating to regulatory filings. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filings. In addition, Amneal is to pay $3 million of development fees to Kashiv as the development work is completed.
The following table includes the expenses recognized for each of the product specific contracts with Kashiv prior to the acquisition of these contracts as part of the KSP transaction.
Amounts in millions
Research and development expenses for three months ended March 31,
ProductsAgreement Date20212020
Levothyroxine Sodium(1)
June 2019$— $— 
K127 (2)
November 2019$$
Posaconazole (3)
May 2020$— $— 
(1) Pursuant to a product development agreement, Amneal and Kashiv agreed to collaborate on the development and commercialization of Levothyroxine Sodium. Under the agreement, the intellectual property and ANDA for this product is owned by Amneal, and Kashiv is to receive a profit share for all sales of the product made by Amneal. Amneal is precluded from selling the product made by Kashiv during the term of the license and supply agreement with Jerome Stevens Pharmaceuticals (refer to Note 5. Alliance and Collaboration, in the Company's 2020 Annual Report on Form 10-K for additional details). Under the terms of the amended agreement with Kashiv, Amneal paid $2 million in July 2019 and may be required to pay up to an additional $18 million upon certain regulatory milestones being met.
(2) Amneal and Kashiv have a licensing agreement for the development and commercialization of Kashiv’s orphan drug K127 (Pyridostigmine) for the treatment of Myasthenia Gravis. Under the terms of the agreement, Kashiv will be responsible for all development and clinical work required to secure Food and Drug Administration approval, and Amneal will be responsible for filing the NDA and commercializing the product. The Company made an upfront payment of approximately $2 million to Kashiv in December 2019, and Kashiv is eligible to receive development and regulatory milestones totaling approximately $17 million. Kashiv is also eligible to receive tiered royalties from the low double-digits to mid-teens on net sales of K127.
(3) Amneal and Kashiv have a product development agreement for the development and commercialization of Posaconazole. In connection with the agreement, Amneal paid an upfront amount of $0.3 million in May 2020 for execution of the agreement. The agreement also provides for potential future milestone payments to Kashiv of (i) up to $0.8 million relating to development milestones, (ii) up to $0.3 million relating to regulatory approval, and (iii) up to $1 million for the achievement of cumulative net sales. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filing, FDA approval and commercial sales volume objectives.
v3.21.1
Goodwill and Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows (in thousands):
March 31,
2021
December 31,
2020
Balance, beginning of period$522,814 $419,504 
Goodwill acquired during the period— 103,679 
Currency translation(56)(369)
Balance, end of period$522,758 $522,814 
Schedule of Finite-Lived Intangible Assets
Intangible assets at March 31, 2021 and December 31, 2020 were comprised of the following (in thousands):
March 31, 2021December 31, 2020
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights8.8$1,149,245 $(360,174)$789,071 $1,153,096 $(328,587)$824,509 
Other intangible assets5.5133,800 (39,312)94,488 133,800 (33,078)100,722 
Subtotal$1,283,045 $(399,486)$883,559 $1,286,896 $(361,665)$925,231 
In-process research and development
379,395 — 379,395 379,395 — 379,395 
Total intangible assets$1,662,440 $(399,486)$1,262,954 $1,666,291 $(361,665)$1,304,626 
Finite-lived Intangible Assets Amortization Expense
Amortization expense related to intangible assets recognized is as follows (in thousands):
Three Months Ended March 31,
20212020
Amortization$41,672 $42,576 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The following table presents future amortization expense for the next five years and thereafter, excluding $379 million of IPR&D intangible assets (in thousands):
Future
Amortization
Remainder of 2021$125,091 
2022155,162 
2023143,395 
2024136,910 
202597,937 
Thereafter225,064 
Total$883,559 
v3.21.1
Stockholders’ Equity and Redeemable Non-Controlling Interests (Tables)
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Loss by Component
Changes in Accumulated Other Comprehensive Loss by Component (in thousands):
Foreign
currency
translation
adjustment
Unrealized
gain (loss) on cash
flow hedge, net
of tax
Accumulated
other
comprehensive
loss
Balance December 31, 2019$(7,832)$7,764 $(68)
Other comprehensive loss before reclassification(6,643)(34,560)(41,203)
Reallocation of ownership interests(22)(25)(47)
Balance December 31, 2020(14,497)(26,821)(41,318)
Other comprehensive loss before reclassification(3,139)10,243 7,104 
Reallocation of ownership interests(52)(95)(147)
Balance March 31, 2021$(17,688)$(16,673)$(34,361)
v3.21.1
Nature of Operations - Additional Information (Details) - Amneal Group
Mar. 31, 2021
Noncontrolling Interest [Line Items]  
Ownership by parent (percent) 49.40%
Amneal Group  
Noncontrolling Interest [Line Items]  
Ownership percentage by noncontrolling owners (percent) 50.60%
v3.21.1
Summary of Significant Accounting Policies (Details)
$ in Millions
Dec. 31, 2020
USD ($)
Accounting Policies [Abstract]  
Financing lease right-of-use assets $ 10
Current portion of financing lease liabilities 2
Long-term lease liabilities $ 2
v3.21.1
Acquisitions and Divestitures - Additional Information (Details) - USD ($)
3 Months Ended
Jan. 11, 2022
Apr. 02, 2021
Jan. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 10, 2019
Business Acquisition [Line Items]                
Goodwill       $ 522,758,000   $ 522,814,000 $ 419,504,000  
AvKARE                
Business Acquisition [Line Items]                
Goodwill       70,000,000   $ 70,000,000    
Generics                
Business Acquisition [Line Items]                
Goodwill       34,000,000        
Term Loan                
Business Acquisition [Line Items]                
Debt, face amount     $ 180,000,000          
Kashiv Specialty Pharmaceuticals, LLC | Forecast                
Business Acquisition [Line Items]                
Consideration paid in cash on hand $ 30,000,000              
Contingent consideration $ 8,000,000              
Kashiv Specialty Pharmaceuticals, LLC | Subsequent Event                
Business Acquisition [Line Items]                
Voting interest acquired (percent)   98.00%            
Consideration paid in cash on hand   $ 70,000,000            
AvKARE and R&S Acquisitions                
Business Acquisition [Line Items]                
Voting interest acquired (percent)     65.10%         65.10%
Consideration paid in cash on hand     $ 254,000,000          
Total consideration, net of cash acquired     294,248,000          
Liabilities incurred, fair value     11,000,000          
Working capital costs     2,000,000          
Acquisition, transaction costs       0 $ 1,000,000      
Goodwill     103,679,000 104,000,000        
AvKARE and R&S Acquisitions | Short Term Promissory Note                
Business Acquisition [Line Items]                
Liabilities incurred     1,000,000          
AvKARE and R&S Acquisitions | Cash on Hand                
Business Acquisition [Line Items]                
Consideration paid in cash on hand     76,000,000          
AvKARE and R&S Acquisitions | Long Term Promissory Notes                
Business Acquisition [Line Items]                
Liabilities incurred     44,000,000          
Liabilities incurred, fair value     35,033,000          
AvKARE and R&S Acquisitions | Debt                
Business Acquisition [Line Items]                
Consideration paid in cash on hand     $ 178,000,000          
AvKARE | AvKARE                
Business Acquisition [Line Items]                
Goodwill       $ 70,000,000        
v3.21.1
Acquisitions and Divestitures - Payments to Acquire Business (Details) - AvKARE and R&S Acquisitions
$ in Thousands
Jan. 31, 2020
USD ($)
Business Acquisition [Line Items]  
Cash $ 254,000
Sellers Notes 11,000
Settlement of Amneal trade accounts receivable from R&S 6,855
Working capital adjustment (2,640)
Fair value consideration transferred 294,248
Short Term Promissory Note  
Business Acquisition [Line Items]  
Short-Term Seller Note 1,000
Long Term Promissory Notes  
Business Acquisition [Line Items]  
Sellers Notes 35,033
Short-Term Seller Note 44,000
Sellers notes discount $ 9,000
v3.21.1
Acquisitions and Divestitures - Preliminary Purchase Price Allocation for the Acquisitions (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Jan. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]        
Goodwill $ 522,758 $ 522,814   $ 419,504
AvKARE and R&S Acquisitions        
Business Acquisition [Line Items]        
Trade accounts receivable, net     $ 46,702  
Inventories     71,908  
Prepaid expenses and other current assets     11,316  
Related party receivables     61  
Property, plant and equipment     5,278  
Goodwill $ 104,000   103,679  
Intangible assets, net     130,800  
Operating lease right-of-use assets - related party     5,544  
Total assets acquired     375,288  
Accounts payable and accrued expenses     62,489  
Related party payables     1,532  
Operating lease liabilities - related party     5,544  
Total liabilities assumed     69,565  
Redeemable non-controlling interests     11,475  
Fair value of consideration transferred     $ 294,248  
v3.21.1
Acquisitions and Divestitures - Acquired Intangible Assets (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values $ 131,000
AvKARE and R&S Acquisitions  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values 130,800
Government licenses | AvKARE and R&S Acquisitions  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values $ 66,700
Weighted-Average Useful Life 7 years
Government contracts | AvKARE and R&S Acquisitions  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values $ 22,000
Weighted-Average Useful Life 4 years
National contracts | AvKARE and R&S Acquisitions  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values $ 28,600
Weighted-Average Useful Life 5 years
Customer relationships | AvKARE and R&S Acquisitions  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values $ 13,000
Weighted-Average Useful Life 10 years
Trade name | AvKARE and R&S Acquisitions  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Values $ 500
Weighted-Average Useful Life 6 years
v3.21.1
Acquisitions and Divestitures - Pro Forma (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
Business Combinations [Abstract]  
Net revenue $ 525,303
Net income 122,521
Net income attributable to Amneal Pharmaceuticals, Inc. $ 115,388
v3.21.1
Revenue Recognition - Additional Information (Details) - customer
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Concentration Risk [Line Items]      
Number of largest customers 3 3  
Customer Concentration Risk      
Concentration Risk [Line Items]      
Number of largest customers 3   3
Revenue from Contract with Customer Benchmark | Three Largest Customers | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk (percent) 82.00% 81.00%  
v3.21.1
Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Net revenue $ 493,105 $ 498,533
Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 312,508 352,586
Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 95,931 87,977
AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 84,666 57,970
International and other | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 399 985
Anti-Infective | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 5,913 13,253
Hormonal | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 106,703 87,481
Hormonal | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 16,796 14,227
Antiviral | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue (7,941) 15,824
Decrease on product sales, lower demand 23,000  
Central Nervous System | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 96,291 101,575
Central Nervous System | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 67,711 68,311
Cardiovascular System | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 35,311 29,679
Gastroenterology | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 19,458 23,536
Oncology | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 19,030 15,966
Metabolic Disease/Endocrine | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 6,557 17,229
Respiratory | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 8,178 10,067
Dermatology | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 12,878 15,245
Other therapeutic classes | US | Generics    
Disaggregation of Revenue [Line Items]    
Net revenue 9,731 21,746
Other therapeutic classes | US | Specialty    
Disaggregation of Revenue [Line Items]    
Net revenue 11,424 5,439
Distribution | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 45,499 31,586
Government Label | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 31,072 21,378
Institutional | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue 5,179 3,413
Other | US | AvKARE    
Disaggregation of Revenue [Line Items]    
Net revenue $ 2,916 $ 1,593
v3.21.1
Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Contract Charge - Backs and Sales Volume Allowances  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period $ 628,804
Provision related to sales recorded in the period 727,258
Credits/payments issued during the period (838,304)
Balance, end of period 517,758
Cash Discount Allowances  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 22,690
Provision related to sales recorded in the period 25,048
Credits/payments issued during the period (25,402)
Balance, end of period 22,336
Accrued Returns Allowance  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 174,984
Provision related to sales recorded in the period 24,786
Credits/payments issued during the period (25,758)
Balance, end of period 174,012
Accrued Medicaid and Commercial Rebates  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 131,088
Provision related to sales recorded in the period 28,770
Credits/payments issued during the period (26,852)
Balance, end of period $ 133,006
v3.21.1
Alliance and Collaboration - Additional Information (Details) - USD ($)
3 Months Ended 69 Months Ended
May 07, 2018
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Expensed to costs of goods sold   $ 301,543,000 $ 313,578,000  
Research and development   48,182,000 36,379,000  
Biosimilar Licensing and Supply Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative arrangement maximum contingent payments amount $ 78,000,000      
Research and development   2,000,000 0  
Astra Zeneca        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Expensed to costs of goods sold   $ 3,000,000 $ 4,000,000  
Astra Zeneca | Forecast        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative arrangement reduced royalty       $ 30,000,000
v3.21.1
Restructuring and Other Charges - Additional Information (Details)
$ in Thousands
3 Months Ended 30 Months Ended
Mar. 31, 2021
USD ($)
employee
Mar. 31, 2020
USD ($)
Dec. 31, 2021
employee
Dec. 31, 2020
USD ($)
Restructuring Cost and Reserve [Line Items]        
Restructuring and other charges | $ $ 363 $ 2,048    
Employee restructuring and separation charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring reserve | $ 1,600     $ 1,600
Other employee severance charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring and other charges | $ $ 400 $ 2,000    
New York Manufacturing Facility | Minimum | Forecast        
Restructuring Cost and Reserve [Line Items]        
Expected reduction to headcount | employee     300  
New York Manufacturing Facility | Maximum | Forecast        
Restructuring Cost and Reserve [Line Items]        
Expected reduction to headcount | employee     350  
New York Manufacturing And New Jersey Packaging Facilities        
Restructuring Cost and Reserve [Line Items]        
Headcount reduction | employee 280      
v3.21.1
Earnings per Share - Computation of Basic and Diluted Earnings (Loss) per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator:    
Net income attributable to Amneal Pharmaceuticals, Inc. $ 6,706 $ 115,067
Denominator:    
Weighted-average shares outstanding - basic (in shares) 148,013 147,180
Effect of dilutive securities:    
Weighted-average shares outstanding - diluted (in shares) 151,220 147,956
Net earnings per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:    
Basic (in usd per share) $ 0.05 $ 0.78
Diluted (in usd per share) $ 0.04 $ 0.78
Stock options    
Effect of dilutive securities:    
Effect of dilutive securities (in shares) 792 230
Restricted stock units    
Effect of dilutive securities:    
Effect of dilutive securities (in shares) 2,415 546
v3.21.1
Earnings per Share - Securities Excluded from Diluted Earnings per Share Computation (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 347 683
Performance stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 5,124 3,054
Class B Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from earnings per share (in shares) 152,117 152,117
v3.21.1
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
May 04, 2018
May 07, 2021
Feb. 28, 2021
Jul. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Subsequent Event [Line Items]                
Income tax expense (benefit)         $ 359 $ (108,173)    
Effective tax rate (percent)         2.40% (810.60%)    
Deferred tax assets, discrete income tax benefit           $ 110,000    
Valuation allowance             $ 423,000  
Net operating loss carryforwards               $ 345,000
Income tax receivable, amount refunded     $ 2,000 $ 106,000        
Income tax receivable, net operating loss carryback related to the CARES act       110,000        
Income tax receivable, interest       $ 4,000        
Percentage of tax receivable agreement paid to other holders of Amneal common units (percent) 85.00%              
Liabilities under tax receivable agreement         $ 206,000   $ 206,000  
Subsequent Event                
Subsequent Event [Line Items]                
Percentage of tax receivable agreement paid to other holders of Amneal common units (percent)   85.00%            
v3.21.1
Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Receivables [Abstract]    
Gross accounts receivable $ 1,072,138 $ 1,291,785
Allowance for credit losses (1,444) (1,396)
Contract charge-backs and sales volume allowances (517,758) (628,804)
Cash discount allowances (22,336) (22,690)
Subtotal (541,538) (652,890)
Trade accounts receivable, net $ 530,600 $ 638,895
v3.21.1
Trade Accounts Receivable, Net - Additional Information (Details) - customer
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Concentration Risk [Line Items]      
Number of largest customers 3 3  
Customer Concentration Risk      
Concentration Risk [Line Items]      
Number of largest customers 3   3
Customer Concentration Risk | Accounts Receivable | Customer A      
Concentration Risk [Line Items]      
Concentration risk (percent) 34.00%   39.00%
Customer Concentration Risk | Accounts Receivable | Customer B      
Concentration Risk [Line Items]      
Concentration risk (percent) 28.00%   26.00%
Customer Concentration Risk | Accounts Receivable | Customer C      
Concentration Risk [Line Items]      
Concentration risk (percent) 22.00%   20.00%
v3.21.1
Inventories - Components of Inventories, Net of Reserves (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 205,874 $ 209,180
Work in process 51,633 40,937
Finished goods 239,501 240,532
Total inventories $ 497,008 $ 490,649
v3.21.1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Liabilities    
Interest rate swap $ 33,131 $ 53,903
Deferred compensation plan liabilities 14,500 14,007
Current Liabilities    
Liabilities    
Deferred compensation plan liabilities 2,000 2,000
Non-current Liabilities    
Liabilities    
Deferred compensation plan liabilities 13,000 12,000
Quoted Prices in Active Markets (Level 1)    
Liabilities    
Interest rate swap 0 0
Deferred compensation plan liabilities 0 0
Significant Other Observable Inputs (Level 2)    
Liabilities    
Interest rate swap 33,131 53,903
Deferred compensation plan liabilities 14,500 14,007
Significant Unobservable Inputs (Level 3)    
Liabilities    
Interest rate swap 0 0
Deferred compensation plan liabilities $ 0 $ 0
v3.21.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Term Loan | Rondo    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt fair value $ 170 $ 172
Term Loan | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt fair value 2,600 2,600
Sellers Notes | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long term debt $ 37 $ 36
v3.21.1
Financial Instruments - Additional Information (Details) - USD ($)
Mar. 31, 2021
Oct. 31, 2019
Derivative [Line Items]    
Net of income taxes, recognized in accumulated other comprehensive loss $ 33,000,000  
Accumulated Other Comprehensive (Loss) Income    
Derivative [Line Items]    
Net of income taxes, recognized in accumulated other comprehensive loss 16,000,000  
Non-Controlling Interests    
Derivative [Line Items]    
Net of income taxes, recognized in accumulated other comprehensive loss $ 17,000,000  
Interest Rate Lock Agreement    
Derivative [Line Items]    
Notional amount   $ 1,300,000,000
v3.21.1
Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Derivative [Line Items]    
Fair Value $ 33,131 $ 53,903
Variable to Fixed Interest Rate Swap | Designated as Hedging Instrument | Other long-term liabilities    
Derivative [Line Items]    
Fair Value $ 33,131 $ 53,903
v3.21.1
Commitments and Contingencies - Additional Information (Details)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 13, 2015
medication
Nov. 06, 2014
representative
Jul. 31, 2020
medication
Mar. 31, 2021
USD ($)
complaint
claim
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
state
claim
case
Jun. 10, 2020
state
Nov. 01, 2019
state
May 10, 2019
state
Apr. 17, 2017
officer
Loss Contingencies [Line Items]                    
Number of sales representatives | representative   1                
Number of pending claims, including third parties | case           880        
Number of cases | case           120        
Number of states with cases           11        
Number of former officers alleging violations | officer                   4
Generic Digoxin and Doxycycline Antitrust Litigation                    
Loss Contingencies [Line Items]                    
Number of generic prescription medications | medication     3              
Number of states, filed civil lawsuit             46   43  
Number of claims filed on behalf of additional states and territories               9    
Ranitidine                    
Loss Contingencies [Line Items]                    
Number of claims dismissed | claim       3   3        
Number of personal injury short form complaints | complaint       190            
United States Department of Justice Investigations                    
Loss Contingencies [Line Items]                    
Number of generic prescription medications | medication 4                  
Commercial and Governmental Legal Proceedings and Claims                    
Loss Contingencies [Line Items]                    
Net charge for legal proceedings | $       $ 0 $ 5          
Liability related to legal proceedings | $       $ 11   $ 11        
v3.21.1
Segment Information - Additional Information (Details)
3 Months Ended
Mar. 31, 2021
segment
product
Segment Reporting [Abstract]  
Number of reportable segments | segment 3
Number of product families | product 250
v3.21.1
Segment Information - Schedules of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]    
Net revenue $ 493,105 $ 498,533
Cost of goods sold 301,543 313,578
Cost of goods sold impairment charges 0 1,456
Gross profit 191,562 183,499
Selling, general and administrative 90,726 77,976
Research and development 48,182 36,379
In-process research and development impairment charges 0 960
Intellectual property legal development expenses 3,582 1,270
Acquisition, transaction-related and integration expenses 2,802 2,575
Charges related to legal matters, net 0 4,500
Restructuring and other charges 363 2,048
Operating income 45,907 57,791
Generics    
Segment Reporting Information [Line Items]    
Net revenue 312,508 352,586
AvKARE    
Segment Reporting Information [Line Items]    
Net revenue 84,666 57,970
Operating Segments | Generics    
Segment Reporting Information [Line Items]    
Net revenue 312,508 352,586
Cost of goods sold 185,298 218,865
Cost of goods sold impairment charges   1,456
Gross profit 127,210 132,265
Selling, general and administrative 18,762 16,623
Research and development 36,117 29,034
In-process research and development impairment charges   960
Intellectual property legal development expenses 3,582 1,265
Acquisition, transaction-related and integration expenses 0 0
Charges related to legal matters, net   2,500
Restructuring and other charges 80 46
Operating income 68,669 81,837
Operating Segments | Specialty    
Segment Reporting Information [Line Items]    
Net revenue 95,931 87,977
Cost of goods sold 48,198 47,818
Cost of goods sold impairment charges   0
Gross profit 47,733 40,159
Selling, general and administrative 19,881 20,942
Research and development 12,065 7,345
In-process research and development impairment charges   0
Intellectual property legal development expenses 0 5
Acquisition, transaction-related and integration expenses 0 0
Charges related to legal matters, net   2,000
Restructuring and other charges 0 0
Operating income 15,787 9,867
Operating Segments | AvKARE    
Segment Reporting Information [Line Items]    
Net revenue 84,666 57,970
Cost of goods sold 68,047 46,895
Cost of goods sold impairment charges  
Gross profit 16,619 11,075
Selling, general and administrative 13,704 10,788
Research and development 0 0
In-process research and development impairment charges   0
Intellectual property legal development expenses 0 0
Acquisition, transaction-related and integration expenses 931 0
Charges related to legal matters, net   0
Restructuring and other charges 0 0
Operating income 1,984 287
Corporate and Other    
Segment Reporting Information [Line Items]    
Net revenue 0 0
Cost of goods sold 0 0
Cost of goods sold impairment charges   0
Gross profit 0 0
Selling, general and administrative 38,379 29,623
Research and development 0 0
In-process research and development impairment charges   0
Intellectual property legal development expenses 0 0
Acquisition, transaction-related and integration expenses 1,871 2,575
Charges related to legal matters, net   0
Restructuring and other charges 283 2,002
Operating income $ (40,533) $ (34,200)
v3.21.1
Related Party Transactions - Additional Information (Details)
1 Months Ended 3 Months Ended
Jun. 01, 2020
USD ($)
Jul. 31, 2019
USD ($)
Mar. 31, 2021
USD ($)
lease_agreement
building
Mar. 31, 2020
USD ($)
Apr. 02, 2021
Dec. 31, 2020
USD ($)
Jun. 06, 2019
USD ($)
product
Related Party Transaction [Line Items]              
Related party payable - short term     $ 20,100,000     $ 7,561,000  
Related party receivables     1,102,000     1,407,000  
Kashiv Specialty Pharmaceuticals, LLC | Subsequent Event              
Related Party Transaction [Line Items]              
Voting interest acquired (percent)         98.00%    
Kashiv BioSciences LLC | Related Party | Kashiv Bio Sciences Generic Pharmaceutical Products Development and Commercialization              
Related Party Transaction [Line Items]              
Expenses from transactions with related party       $ 0      
Kashiv BioSciences LLC | Related Party | Maximum              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     100,000        
Kashiv BioSciences LLC | Related Party | Maximum | Kashiv Bio Sciences Generic Pharmaceutical Products Development and Commercialization              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     100,000        
Avtar Investments, LLC | Related Party              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     100,000 0      
Related parties payable (less than)     $ 100,000     100,000  
Related Party              
Related Party Transaction [Line Items]              
Number of buildings, financing lease | building     2        
Lease costs     $ 200,000 1,000,000      
Interest expense     $ 400,000 1,000,000      
Related Party | Kanan, LLC              
Related Party Transaction [Line Items]              
Number of lease agreements | lease_agreement     2        
Related Party | Kanan, LLC | Annual Rental Cost              
Related Party Transaction [Line Items]              
Amounts of transaction with related party     $ 2,000,000        
Related Party | Kanan, LLC | Rent Expense              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     500,000 500,000      
Related Party | Industrial Real Estate Holdings NY, LLC              
Related Party Transaction [Line Items]              
Lease renewal term 5 years            
Related Party | Industrial Real Estate Holdings NY, LLC | Rent Renewal Fee              
Related Party Transaction [Line Items]              
Expenses from transactions with related party $ 100,000            
Related Party | Industrial Real Estate Holdings NY, LLC | Rent Expense              
Related Party Transaction [Line Items]              
Expenses from transactions with related party $ 100,000   300,000 300,000      
Annual rent increase (percent) 3.00%            
Related Party | Kashiv BioSciences LLC              
Related Party Transaction [Line Items]              
Related party payable - short term     8,000,000     5,000,000  
Related party receivables           100,000  
Related Party | Kashiv BioSciences LLC | Development And Commercialization Reimbursable Expense              
Related Party Transaction [Line Items]              
Amounts of transaction with related party     100,000 200,000      
Related Party | Kashiv BioSciences LLC | Cost Of Goods Sold and R&D Reimbursement              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     1,000,000 1,000,000      
Related Party | Kashiv Pharmaceuticals LLC | Profit Share On Various Arrangements              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     3,000,000 3,000,000      
Related Party | PharmaSophia, LLC              
Related Party Transaction [Line Items]              
Related party receivables     $ 1,000,000     800,000  
Ownership interest (percent)     50.00%        
Income from related parties     $ 300,000 200,000      
Related Party | Fosun International Limited | Non-Refundable Fee, Net of Tax              
Related Party Transaction [Line Items]              
Payment received, non-refundable fee   $ 1,000,000          
Related Party | Fosun International Limited | Fee Due Upon First Commercial Sale Of Products              
Related Party Transaction [Line Items]              
Additional amount due from related parties upon sale of each product             $ 300,000
Additional amount due from related parties upon sale of each product, number of products | product             8
Related Party | Zep Inc.              
Related Party Transaction [Line Items]              
Related party receivables     0     100,000  
Apace KY, LLC              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     2,000,000 2,000,000      
Related party payable - short term     1,000,000.0     1,000,000.0  
Related party receivables     100,000     500,000  
Tracy Properties LLC              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     100,000 100,000      
AzaTech Pharma LLC              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     1,000,000 800,000      
Related party payable - short term     700,000     $ 1,000,000  
AvPROP, LLC              
Related Party Transaction [Line Items]              
Expenses from transactions with related party     $ 100,000 $ 100,000      
AvKARE, LLC | Rondo              
Related Party Transaction [Line Items]              
Ownership interest (percent)     34.90%        
v3.21.1
Related Party Transactions - Product Specific Terms and Expenses with Kashiv (Details)
$ in Millions
1 Months Ended 3 Months Ended
Aug. 31, 2020
USD ($)
product
Oct. 31, 2017
USD ($)
product
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Filgrastim and PEG-Filgrastim        
Related Party Transaction [Line Items]        
Collaborative arrangement term   10 years    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim        
Related Party Transaction [Line Items]        
Amounts of transaction with related party     $ 0.0 $ 0.0
Number of products in agreement | product   2    
Collaborative arrangement, profit share (percent)   50.00%    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim | Regulatory Approval        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount   $ 21.0    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim | Successful Delivery of Commercial Launch Inventory        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount   43.0    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim | Number of Competitors for Launch of one Product | Minimum        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount   20.0    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim | Number of Competitors for Launch of one Product | Maximum        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount   50.0    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim | Achievement of Cumulative Net Sales | Minimum        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount   15.0    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Filgrastim and PEG-Filgrastim | Achievement of Cumulative Net Sales | Maximum        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount   $ 68.0    
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Ganirelix Acetate and Cetrorelix acetate        
Related Party Transaction [Line Items]        
Amounts of transaction with related party     $ 1.0 $ 0.0
Number of products in agreement | product 2      
Collaborative arrangement, upfront payment $ 1.0      
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Ganirelix Acetate and Cetrorelix acetate | Regulatory Approval        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount 0.3      
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Ganirelix Acetate and Cetrorelix acetate | Development Milestones        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount 2.0      
Kashiv BioSciences LLC | R&D Reimbursement | Related Party | Ganirelix Acetate and Cetrorelix acetate | Development Fees        
Related Party Transaction [Line Items]        
Collaborative arrangement maximum contingent payments amount $ 3.0      
v3.21.1
Related Party Transactions - Product Specific Contracts with Kashiv Prior to the Acquisition (Details) - Kashiv BioSciences LLC - R&D Reimbursement - Related Party - USD ($)
$ in Millions
1 Months Ended 3 Months Ended
May 31, 2020
Dec. 31, 2019
Jul. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Levothyroxine Sodium          
Related Party Transaction [Line Items]          
Expenses from transactions with related party       $ 0.0 $ 0.0
Amounts of transaction with related party     $ 2.0    
Additional amount due to related party, if circumstances met (up to)     $ 18.0    
K127          
Related Party Transaction [Line Items]          
Expenses from transactions with related party       3.0 2.0
Collaborative arrangement, upfront payment   $ 2.0      
K127 | Regulatory Approval          
Related Party Transaction [Line Items]          
Collaborative arrangement maximum contingent payments amount   $ 17.0      
Posaconazole          
Related Party Transaction [Line Items]          
Expenses from transactions with related party       $ 0.0 $ 0.0
Collaborative arrangement, upfront payment $ 0.3        
Posaconazole | Regulatory Approval          
Related Party Transaction [Line Items]          
Collaborative arrangement maximum contingent payments amount 0.3        
Posaconazole | Development Milestones          
Related Party Transaction [Line Items]          
Collaborative arrangement maximum contingent payments amount 0.8        
Posaconazole | Achievement of Cumulative Net Sales          
Related Party Transaction [Line Items]          
Collaborative arrangement maximum contingent payments amount $ 1.0        
v3.21.1
Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Goodwill [Roll Forward]    
Balance, beginning of period $ 522,814 $ 419,504
Goodwill acquired during the period 0 103,679
Currency translation (56) (369)
Balance, end of period $ 522,758 $ 522,814
v3.21.1
Goodwill and Intangible Assets - Additional Information (Detail)
3 Months Ended
Mar. 31, 2021
USD ($)
product
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Goodwill [Line Items]      
Goodwill $ 522,758,000 $ 522,814,000 $ 419,504,000
Impairment charges 0    
Intangible assets acquired $ 131,000,000    
In-process research and development      
Goodwill [Line Items]      
Intangible assets impairment, number of products experiencing impairment | product 2    
Intangible assets impairment, number of in process products experiencing estimated launch date delays | product 1    
Marketed products      
Goodwill [Line Items]      
Intangible assets impairment, number of products experiencing impairment | product 2    
Intangible assets impairment, number of products experiencing price erosion | product 2    
Specialty      
Goodwill [Line Items]      
Goodwill $ 361,000,000 361,000,000  
Generics      
Goodwill [Line Items]      
Goodwill 92,000,000 92,000,000  
AvKARE      
Goodwill [Line Items]      
Goodwill $ 70,000,000 $ 70,000,000  
v3.21.1
Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,283,045 $ 1,286,896
Accumulated Amortization (399,486) (361,665)
Total 883,559 925,231
In-process research and development 379,395 379,395
Intangible assets, cost 1,662,440 1,666,291
Intangible assets, net 1,262,954 1,304,626
In-process research and development    
Finite-Lived Intangible Assets [Line Items]    
Accumulated Amortization $ 0 0
Product rights    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period (in years) 8 years 9 months 18 days  
Cost $ 1,149,245 1,153,096
Accumulated Amortization (360,174) (328,587)
Total $ 789,071 824,509
Other intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period (in years) 5 years 6 months  
Cost $ 133,800 133,800
Accumulated Amortization (39,312) (33,078)
Total $ 94,488 $ 100,722
v3.21.1
Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization $ 41,672 $ 42,576
v3.21.1
Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]    
In-process research and development $ 379,395 $ 379,395
Remainder of 2021 125,091  
2022 155,162  
2023 143,395  
2024 136,910  
2025 97,937  
Thereafter 225,064  
Total $ 883,559 $ 925,231
v3.21.1
Stockholders' Equity and Redeemable Non-Controlling Interests - Additional Information (Details) - USD ($)
3 Months Ended
Jan. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 10, 2019
Class of Stock [Line Items]        
Tax distribution   $ 9,000,000 $ 0  
Tax distribution recorded as a reduction to redeemable non-controlling interest   $ 500,000 $ 0  
AvKARE and R&S Acquisitions        
Class of Stock [Line Items]        
Voting interest acquired (percent) 65.10%     65.10%
Liabilities incurred, fair value $ 11,000,000      
AvKARE and R&S Acquisitions | Rondo        
Class of Stock [Line Items]        
Ownership percentage by noncontrolling owners (percent) 34.90% 34.90%    
v3.21.1
Stockholders' Equity and Redeemable Non-Controlling Interests - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance $ 344,932 $ 346,788
Other comprehensive loss before reclassification 7,104 (41,203)
Reallocation of ownership interests (147) (47)
Stockholders' equity ending balance 366,708 344,932
Foreign currency translation adjustment    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance (14,497) (7,832)
Other comprehensive loss before reclassification (3,139) (6,643)
Reallocation of ownership interests (52) (22)
Stockholders' equity ending balance (17,688) (14,497)
Unrealized gain (loss) on cash flow hedge, net of tax    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance (26,821) 7,764
Other comprehensive loss before reclassification 10,243 (34,560)
Reallocation of ownership interests (95) (25)
Stockholders' equity ending balance (16,673) (26,821)
Accumulated Other Comprehensive (Loss) Income    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Stockholders' equity beginning balance (41,318) (68)
Stockholders' equity ending balance $ (34,361) $ (41,318)
v3.21.1
Subsequent Events - Additional Information (Details)
Apr. 02, 2021
Subsequent Event | Kashiv Specialty Pharmaceuticals, LLC  
Subsequent Event [Line Items]  
Voting interest acquired (percent) 98.00%